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ABSTRACT 
 
Iron is an essential functional element for several biologic processes, such as 
energy production and intermediate metabolism. However, when in excess, it can be toxic 
and produce free radicals. Deregulation of iron homeostasis has been consistently linked 
to the pathogenesis of chronic diseases. Cancer cells are thought to have higher 
requirements for iron. The importance of iron in tumor cell proliferation is demonstrated by 
the higher numbers of transferrin receptors than their 'normal' counterparts and by the fact 
that some iron chelators can suppress the growth of aggressive tumors.  
It is generally accepted that invasive breast cancer develops from benign disease. 
Nevertheless, the progression from carcinoma in situ to invasive cancer remains poorly 
understood. While genetic and epigenetic alterations known to regulate cell proliferation, 
differentiation and/ or survival are the most likely initiators of breast carcinogenesis and 
since most ductal breast carcinoma cells are weakly invasive in vitro it is likely that stromal 
cell responses in premalignant stages may facilitate progression to invasive cancer. In this 
respect, the contribution of leukocytes to the regulation of the tumor microenvironment 
iron regulation had not been addressed before. Given the fact that circulating leukocytes 
besides taking up iron for their own survival are capable of exporting it in some conditions, 
we hypothesized that stromal inflammatory cells, by constituting a potential iron delivery 
system, may have an important role in breast cancer progression. 
In the present study, we evaluated the cellular expression of iron-related proteins 
in the context of breast cancer microenvironment by immunohistochemistry and flow 
cytometry and analyzed possible association with tissue iron deposition and HFE 
genotype. 
Results of the work showed that, as expected, breast cancer epithelial cells 
present an ‘iron-utilization phenotype’ with an increased expression of hepcidin and 
transferrin receptor 1 (TFR1), and decreased expression of ferritin (FT). In turn, 
lymphocytes and macrophages infiltrating primary tumors and from metastized lymph 
nodes display an ‘iron-donor’ phenotype with increased expression of ferroportin 1 (FPN1) 
and FT complemented by an activation status, as reflected by a higher expression of 
TFR1 and hepcidin. This phenotype is supported by the higher percentage of breast 
carcinomas presenting iron accumulation in stromal inflammatory cells. Furthermore, the 
deregulated expression of iron-related proteins in lymphocytes and macrophages is also 
associated with hormone receptor status and tumor size.  
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The chemokine (C-C motif) ligand 2 (CCL2) has an established role in leukocyte 
recruitment into the tumor microenvironment and has been recently described as a 
modulator of tissue iron levels. Epithelial CCL2 expression, which is increased in breast 
carcinomas samples, was also significantly higher in samples presenting iron deposition in 
stromal inflammatory cells. In fact, besides being associated with an increased infiltration 
of lymphocytes and CCL2-positive macrophages, its expression was also correlated with 
FPN1 expression in lymphocytes. These relationships suggest the existence of a 
paracrine signaling pathway where CCL2 may play an indirect role regulating tumor iron 
nutrition and progression.  The median CCL2 expression in epithelial cells is not 
significantly different between patients presenting the HFE p.C282Y or p.H63D variants. 
However, p.C282Y/H63D compound heterozygous invasive carcinoma patients exhibit a 
higher expression of hepcidin in lymphocytes and macrophages and of TFR1 in all the cell 
types analyzed. 
Surprisingly, the expression of iron-related proteins is not significantly different 
between benign and malignant mammary gland lesions obtained from cats and dogs. The 
lack of cancer cells’ higher iron requirements may be explained by the fact that normal 
mammary gland from both species present strong iron deposition, unlike what happens in 
human samples.  
In conclusion, our results reinforce the need to study the tumor microenvironment 
in breast cancer, while extending the knowledge of the contribution of immune cells to the 
local iron homeostasis in the tumor microenvironment context. Furthermore, the 
replication of the original study to other animal models allowed us to detect important 
physiological differences regarding the human breast tissue, demanding a more insightful 
knowledge of systemic and local iron homeostasis in cats and dogs. 
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RESUMO 
 
O ferro é um elemento essencial em vários processos biológicos, incluindo a 
produção de energia e o metabolismo secundário. No entanto, quando em excesso, pode 
ser tóxico e levar à produção de radicais livres. A desregulação dos mecanismos 
homeostáticos dos níveis de ferro tem sido associada à patogénese de doenças crónicas, 
como o cancro. A importância do ferro na proliferação celular neoplásica é confirmada 
pela evidência de número superior de receptores da transferrina 1 em comparação com 
células não neoplásicas, e pelo facto de alguns agentes quelantes de ferro serem 
capazes de suprimir o crescimento de tumores mais agressivos. 
É geralmente aceite que o carcinoma invasor da mama se desenvolve a partir de 
alterações benignas na mama. No entanto, a progressão de carcinoma in situ para 
carcinoma invasor permanece relativamente incompreendida. Enquanto as alterações 
genéticas e epigenéticas que regulam a proliferação celular, diferenciação e/ ou 
sobrevivência desempenham um papel crucial na iniciação do processo de 
carcinogénese, durante a invasão as interacções com as células do estroma são 
essenciais, dado que as células de carcinoma da mama têm um potencial de invasão 
limitado in vitro. Neste contexto, a contribuição dos leucócitos para a regulação do ferro 
no microambiente tumoral ainda não foi abordada. Dado que os leucócitos são células 
capazes não só de internalizar ferro para a sua própria sobrevivência, mas também de o 
exportar em determinadas condições, levantámos a hipótese que as células inflamatórias 
do estroma poderiam contribuir para a progressão do carcinoma da mama através da 
distribuição local de ferro. 
Neste estudo, avaliámos a expressão de proteínas envolvidas na regulação 
celular do ferro no microambiente tumoral da mama por imunohistoquímica e citometria 
de fluxo e analisámos possíveis associações com a deposição de ferro no tecido e com a 
presença de variantes do gene HFE. 
Como descrito anteriormente, verificámos que as células epiteliais de carcinoma 
da mama apresentam um perfil de utilização de ferro, através uma maior expressão de 
hepcidina e receptor da transferrina 1, e uma menor expressão de ferritina. Por sua vez, 
linfócitos e macrófagos presentes no infiltrado inflamatório e em nódulos linfáticos 
metastizados exibem um perfil doador de ferro, com uma expressão aumentada de 
ferroportina 1 e ferritina. Simultaneamente, a expressão elevada de hepcidina e receptor 
de transferrina 1 sugerem a activação destes tipos celulares. Este fenótipo é corroborado 
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pelo facto que, comparativamente com amostras de mamoplastias estéticas de redução, 
uma maior percentagem de casos de carcinoma da mama apresenta acumulação de 
ferro em células inflamatórias do estroma. Adicionalmente, alterações na expressão 
destas proteínas reguladoras do metabolismo celular do ferro estão associadas com o 
status dos receptores hormonais e tamanho do tumor na altura do diagnóstico. 
O CCL2 é uma citocina pertencente à família das quimiocinas C-C com um papel 
comprovado como recrutadora de leucócitos para o microambiente tumoral. 
Recentemente foi descrito que esta também seria capaz de modelar os níveis locais de 
ferro no tecido. A expressão de CCL2 nas células epiteliais, previamente descrita como 
aumentada em casos de carcinoma da mama e confirmado no nosso estudo, foi 
demonstrada aqui ser também significativamente superior nos casos que apresentam 
deposição de ferro nas células inflamatórias do estroma. De facto, para além da 
expectável associação com a infiltração de linfócitos e macrófagos CCL2-positivos, a 
expressão de CCL2 está também correlacionada com a expressão de ferroportina 1 nos 
linfócitos. Estas relações sugerem a existência de uma via de sinalização parácrina onde 
o CCL2 pode ter um papel indirecto na regulação da nutrição e progressão tumoral. Os 
níveis de expressão de CCL2 no tecido mamário não são significativamente diferentes 
em doentes com as variantes p.C282Y e/ou p.H63D do gene HFE. No entanto, doentes 
heterozigóticas compostas p.C282Y/p.H63D apresentam uma maior expressão de 
hepcidina em linfócitos e macrófagos do infiltrado inflamatório, bem como de receptor da 
transferrina 1 nos tipos celulares analisados. 
Surpreendentemente, a expressão das proteínas reguladoras do metabolismo do 
ferro não é significativamente diferente entre lesões mamárias benignas e malignas em 
amostras de gatas e cadelas. A observação de que as células tumorais mamárias de 
gatas e cadelas não apresentam maiores exigências de ferro do que as suas congéneres 
benignas pode ser explicada pelo facto de que a glândula mamária normal destas 
espécies apresenta já uma forte acumulação de ferro, ao contrário do que se verifica na 
espécie humana.  
Em conclusão, os nossos resultados reforçam a necessidade de estudar o 
microambiente tumoral no carcinoma da mama, enquanto ampliam o conhecimento sobre 
a contribuição das células do sistema imune para a regulação local do ferro, em contexto 
tumoral. Adicionalmente, a translação do estudo original em animais modelo de 
carcinoma da mama permitiu-nos detectar diferenças fisiológicas nas mamas das gatas e 
cadelas em relação à mama da mulher, levantando a necessidade de um conhecimento 
mais aprofundado sobre a regulação sistémica e local da homeostasia do ferro nestas 
espécies. 
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1.1. Breast Cancer 
 
1.1.1. The Human Breast 
The breast is a dynamic organ that suffers several changes during the embryonic 
development, puberty, pregnancy, lactation and involution. The development of the ductal 
system is termed branching morphogenesis, and although it starts in the fetus, it is only 
completed during puberty when hormonal stimulation triggers differentiation [1, 2]. Under 
hormonal influence, complex reciprocal interactions between epithelial and stromal cells 
drive the alterations observed in the mammary gland in a woman’s lifetime. 
The adult female breast lies on the anterior chest wall, over the pectoralis major 
muscle, and  is placed normally between the 2nd and 6th ribs  of the chest wall in the 
vertical axis and between the sterna edge and the midaxillary line in the horizontal axis [3, 
4]. The breast also extends superolaterally to the axilla [5].  
The breast is composed by 15-20 lobes, each one drained by a collecting duct. 
These collecting ducts link the nipple with lactiferous sinus, that by its turn are connected 
to terminal duct-lobular units (TDLUs), the breast functional unit, by lactiferous and major 
ducts. Lobules consist of TDLUs, acini and their underlying, hormone-responsive, 
supporting stroma, consisting of various proportions of fibrous and adipose tissue [6] 
(Figure 1). 
Except for a part of the collecting ducts near the nipple, composed of squamous 
epithelium, the ductal system consists of two main epithelial layers: an inner ductal layer 
composed of columnar luminal epithelial cells and an outer spindle-shaped myoepithelial 
cell layer. The epithelial cells of the inner layer are typically immunoreactive for low 
molecular weight cytokeratins (CK) 8, 18 and 19 and characterized by a cytoplasm with 
abundant organelles involved in secretion. The outer layer is characterized by the 
expression of high molecular weight CKs 5/6, anti-actin antibodies and p63, in close 
contact with the basal lamina [3, 4]. Myoepithelial cells are responsible not only by the 
maintenance of the ductal structure but also by assisting milk ejection [7]. The basal 
lamina in conjunction with the epithelial-myoepithelial cell layers and the surrounding zone 
of delimitating fibroblasts is denominated of epithelial-stromal junction [3].  Lymphocytes, 
plasma cells and macrophages normally lie in the interstices of this fibroblast network, 
which facilitates cell-cell interactions [8]. The intralobular stroma is more cellular and 
contains more vessels than the interlobular stroma, while the latter is more collagenized 
[3, 4]. The complex lymphatic network present in the mammary gland is drained, mostly, 
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to the axillary lymph nodes, which facilitates epithelial cell spread in the case of metastatic 
disease [9]. 
1.1.2. Breast Cancer 
Breast female lesions are frequent. As fear of cancer is very common, use of 
image technology in screening is generalized and identifies most of the lesions, when no 
clinical manifestation still exists. If present, they manifest as palpable nodules or masses 
[12]. Although most of known epithelial benign and malignant lesions of the breast arise at 
the level of the TDLU other common breast diseases also have origin in other sites 
[13](Table 1). 
 
 
 
 
 
Figure 1. A. Schematic representation of the main anatomic features in an adult woman’s breast.  
Adapted from [10]. B-D. Mammary gland characteristic histological elements, highlighting the 
ducts, connective and adipose tissue, lobules and acini. Adapted from [2, 11]. 
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Table 1. Origin sites for common breast diseases. Adapted from [13]. 
Nipple 
 Paget’s Disease 
 Nipple Adenoma 
Lactiferous Ducts 
 Subsclerosing Duct Hyperplasia 
 Duct Ectasia 
Segmental and Subsegmental Ducts 
 Solitary Intraductal Papilloma 
 Duct Ectasia 
Terminal Duct Lobular Units 
 Cyst 
 Epithelial Hyperplasia 
 Noninvasive and Invasive Carcinoma 
 
Fibrocystic changes are the most common alterations in the adult premenopausal 
women and thought to be caused by breast alterations during menstruation cycles [12]. 
Although of little clinical significance, some benign changes may confer an increased risk 
for the development of breast cancer [14-16]. 
Even though the exact mechanisms involved in the development of breast cancer 
remain unknown, the most commonly accepted model hypothesizes that invasive cancer 
starts in the TDLU [17] and progresses through pre-malignant breast disease by 
increasing cellular anomalies leading to exaggerated proliferation and atypia [18-20]. A 
proliferative growth advantage in flat epithelial atypia (FEA) can then give rise to atypical 
ductal hyperplasia (ADH) that may progress to ductal carcinoma in situ (DCIS) upon 
additional molecular alterations [21, 22]. Several epidemiologic studies support this 
stepwise model of progression in which invasiveness arises through the accumulation of 
abnormalities in benign breast diseases [14, 16, 23, 24]. Each stage is considered to 
result from genetic alterations in a transformed clonal lineage, eventually capable of 
invasion and metastasis [25]. Furthermore, matched genetic and epigenetic alterations 
are frequently found in proliferative diseases without atypia (PDWA), ADH, DCIS and 
invasive breast cancer (IBC) in the same breast [18, 26-28], supporting a sequential 
relation between precursor lesions and the IBC with which they are associated [25]. 
Surprisingly, morphologically normal terminal duct lobules adjacent to breast cancer may 
already present loss of heterozygosity (LOH) in genes critical for early progression of 
tumorigenesis [29]. However, the exact place and how DCIS progresses to IBC remains a 
matter of discussion, with two theories attempting to explain it (Figure 2). The theory of 
linear progression states that low-grade DCIS evolves linearly to high-grade DCIS and this 
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is the entity accountable for the progression to IBC [15, 30-32]. On the other hand, the 
theory of parallel disease hypothesizes that low-grade DCIS progresses to low-grade IBC, 
while high-grade DCIS evolves to high-grade IBC, implying a commitment of a particular 
type of DCIS to its IBC counterpart [33]. This model is supported by cytogenetic studies 
showing that specific patterns of chromosomal alterations in particular grades of DCIS 
correspond to distinct genomic changes in matching IBCs [34, 35] and that the degree of 
DCIS differentiation was correlated with that of the corresponding IBC [36]. However, the 
concept that these two models are mutually exclusive may underestimate the complexity 
of the process [37]. 
Figure 2. Stepwise model of breast cancer development highlighting the two views of progression 
from ductal carcinoma in situ to invasive breast carcinoma (Theory of Linear Progression and 
Theory of Parallel Disease). Abbreviations: FEA, flat epithelial atypia; HUT, hyperplasia of usual 
type; ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; DCISlow, low-grade ductal 
carcinoma in situ; DCIShigh, high-grade ductal carcinoma in situ; IBC, invasive breast cancer; 
IBClow, low-grade invasive breast cancer; IBChigh, high-grade invasive breast cancer. 
 
 
1.1.2.1. Epidemiology 
Besides major efforts for disease prevention and treatment, cancer is still a main 
public health problem. In 2012, 3.4 million new cancer cases were diagnosed and 1.75 
million people died of neoplastic disease worldwide [38]. Breast cancer is the most 
commonly diagnosed type of cancer, closely followed by colorectal cancer [38, 39]. 
In women, breast cancer is by far the most frequently diagnosed neoplasm, 
representing nearly 30% of the total, and ranks as the fifth cause of cancer-related death 
[38, 39]. Populations at higher risk of incidence and mortality are situated in Northern 
America, Western and Northern Europe (Figure 3A). Although presenting a slightly higher 
prevalence than the mean established for European Union countries, Portugal follows the 
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tendency, with breast cancer representing the most frequently diagnosed type of cancer 
and cause of cancer death in women (Figure 3B). In Portugal, in 2012, 6066 new cases of 
breast cancer were diagnosed, with 1570 women succumbing to the disease [39]. 
Although breast cancer mortality rates have been decreasing since the 1990’s, 
specifically due to increasingly efficient screening regimens detecting the disease as early 
as possible, its high incidence demands a greater awareness and investment in treatment 
and education. 
Figure 3. A. Breast cancer age-standardized rate (ASR) of incidence and mortality, per 100000 
habitants, in the World. B. Age-standardized rate of incidence and mortality of the top 20 most 
common types of cancer in Portugal. From [39]. 
 
1.1.2.2. Risk Factors 
Several factors have been consistently associated with an increased risk for the 
development of breast cancer. Although the following do not deplete the list of possible 
influencing factors, they clearly highlight the multifactorial etiology of the disease. Breast 
cancer risk factors can be divided in two main groups. The first includes inherent factors 
such as age, gender and family history. The second relates to extrinsic factors influenced 
by the woman’s lifestyle that may condition the neoplastic context to a certain degree [40]. 
Next, a table summarizing the main established risk factors for breast cancer is presented. 
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Table 2. Breast Cancer Risk Factors. 
Intrinsic Factors 
Gender 
 
Personal History 
 
Genetic Predisposition 
 
 
Age 
Family History 
 
 
Other Breast Diseases 
 
Early Menarche 
 
Parity, age of full term pregnancy and breast-
feeding 
 
Age at menopause 
 
Race 
 
 
Testosterone 
 
 
 
 Breast cancer is predominantly diagnosed in 
women [41]. 
 Previous history of DCIS, hormone receptor 
negative IDC and young age [42]. 
 Genes in which mutations increase risk: Breast 
cancer genes (BRCA) 1 and 2, P53, PTEN, 
STK11, CDH-1 [43-47]. 
 Risk increases with age [48, 49]. 
 Increased in case of history of affected first-
degree relatives, particularly at young age (<50 
y.) [50, 51]. 
 Proliferative diseases, especially with atypia 
confer a substantial increased risk [15, 52]. 
 2 y. delay in menarche corresponds to a risk 
reduction of 10% [53]. 
 Nulliparousity, parity at an older age (>35 y.) and 
absence of breast-feeding increases risk [49, 54, 
55]. 
 Every year delay increases the risk by 3% [53, 
56]. 
 Higher rate of mortality in Black women, due to 
higher incidence of triple-negative (TN) tumors 
[49]. 
 High circulating levels of testosterone in 
postmenopausal women increase risk [57]. 
 
Extrinsic Factors 
Hormone Replacement Therapy (HRT) 
 
 
Obesity 
 
Physical Activity 
 
Alcohol Consumption 
Radiation 
 
 Breast cancer risk is higher in hormone 
replacement therapy (HRT) users, especially 
when started close to menopause [58, 59]. 
 Elevated risk with increasing weight, body mass 
index and hip circumference [58, 60]. 
 Physical activity reduces risk in a dose-
dependent manner [61, 62]. 
 Increased risk with binge drinking [63]. 
 Radiation exposure at young age (<35 y.) 
increases risk [64-66]. 
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1.1.2.3. Carcinoma In Situ 
Carcinoma in situ is a non-obligate precursor of invasive carcinoma, characterized 
by an abnormal proliferation of epithelial cells confined in the ductal system by the 
basement membrane, without invasion of the surrounding stroma [67, 68]. The presence 
of malignant epithelial cells beyond the basement membrane is routinely recognized as 
individual cells or irregular nests through the stroma. The disruption of the myoepithelial 
layer may be demonstrated by the absence of myoepithelial cell markers such as p63, 
calponin or smooth muscle myosin [69]. 
Initially, carcinomas in situ were divided into lobular carcinomas in situ (LCIS) and 
ductal carcinomas in situ based on the assumption that these preinvasive lesions were 
generated either on lobules or on ducts, respectively. However, studies by Wellings and 
collaborators revealed that most of the lesions arised in the TDLU, marking the end of the 
distinction between ductal and lobular subtypes [17, 70, 71], which is merely 
morphological. The characteristic histological aspect of ‘historic’ LCIS is hallmarked by the 
absence of E-cadherin expression. However, it is not an exclusive aspect, with DCIS also 
demonstrating E-cadherin loss [72].  
Through the observation of nuclear atypia DCIS can be further classified in low, 
intermediate and high-grade groups [21, 23, 68]. Historically, the architectural pattern of 
the DCIS was described and it correlated well with several tumor markers. Categories 
included non-comedo (cribiform, papillary, micropapillary and papillary) and comedo-
subtypes [73]. The comedo subtype was characterized by the presence of central ductal 
necrosis and high-grade cells, and associated with estrogen receptor (ER) negativity, 
Human Epidermal growth factor Receptor 2 (HER2) amplification, p53 mutations and a 
high proliferation rate [74-79]. With the increasing number of diagnosed DCIS, became 
apparent that the classification in comedo/ non-comedo was not adequate to classify, for 
example lesions with central necrosis and low-grade cell pleomorphism. The need for 
refinement led to several proposed classification schemes until the one in effect today [80, 
81]. Size of the lesion is also an important histological parameter to include in the breast 
pathology report given its clinical significance [68]. Until the 1980’s DCIS was rarely 
diagnosed and represented less than 1% of detected breast cancers [82]. However, with 
the introduction of efficient mammography screening regimens detection of early breast 
cancer improved significantly. Nowadays, DCIS constitutes 20-25% of newly diagnosed 
breast cancer in the United States of America [83]. Implementation of screening 
mammography led to a significant reduction of the average size of DCIS lesion at 
presentation, diminishing from 60 to 10mm [84]. In spite of a clear increase in the 
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incidence of DCIS in the last 25 years, with concomitant improved treatments and 
outcomes, a consequent reduction in the incidence of invasive breast cancer has not 
occurred [83].  
Most women do not present symptoms at the time of DCIS diagnosis, with the 
lesion being detected as a mammographic abnormality. Usual clinical symptoms include 
breast lumps, nipple discharge or Paget’s disease [85]. Accurate diagnosis of DCIS and 
exclusion of invasion breast cancer is critical in order to determine the most adequate 
treatment [69]. 
Historically, DCIS treatment was achieved by simple mastectomy, with success 
rates over 99% [86]. However, mastectomy is associated with a poor body image and 
quality of life [87, 88]. Although it still remains a treatment option, especially in extensive 
DCIS [69], successful treatment of IBC with breast-conserving therapy suggests that DCIS 
may be overtreated [89-92].Thus, after promising results from the National Surgical 
Adjuvant Breast and Bowel Program (NSABP) B17 study, breast-conserving therapy was 
established as the standard of care for DCIS [90, 91]. The efficacy of radiation to reduce 
the risk of breast cancer recurrence after breast-conserving therapy has been clearly 
demonstrated [93-95], with a 15.2% reduced 10-year risk of any ipsilateral breast event 
[95]. Although randomized controlled trials describe a decrease in the number of 
ipsilateral and contralateral breast cancer events, the use of tamoxifen after breast-
conserving surgery for DCIS remains controversial due to toxicity concerns. Since these 
studies have not demonstrated an increase in mortality, the National Comprehensive 
Cancer Network Guidelines recommended the use of tamoxifen for 5 years for ER-
positive DCIS [96, 97]. 
 
1.1.2.4. Invasive Carcinoma 
Invasive breast cancer constitutes a heterogeneous and complex disease that 
includes several pathologies, with different histological characteristics, as supported by 
the variable outcomes in diagnosed patients [23, 98]. The current definition of invasive 
breast cancer lies on the observation of malignant cancer cell spread, through breach of 
the myoepithelial cell layer and basement membrane to the adjacent stroma [99, 100]. 
Invasive carcinomas of the breast are classified according to specific 
morphological features. The majority of these are included in the category of ‘invasive 
carcinoma, no special type’ (NST) also known as invasive ductal carcinoma (IDC) [98, 
101-103]. This group is very heterogeneous, in such a way, that the identification alone 
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does not provide prognostic and predictive information. Special type invasive carcinomas 
constitute approximately 25% of all breast cancers and display a particular morphology 
that is present in, at least, 90% of the tumor [101-103] (Box 1). 
Box 1. Most common breast cancer histological subtypes, based on the World Health 
Organization classification of breast tumors. Adapted from [101, 102]. 
Invasive carcinoma, no special type 
Invasive tubular and cribiform carcinoma 
Medullary carcinoma 
Invasive lobular carcinoma 
Invasive mucinous carcinoma 
Neuroendocrine carcinoma 
Invasive papillary and micropapillary carcinoma 
Metaplastic carcinoma 
Apocrine carcinoma 
Adenoid cystic carcinoma 
 
Diagnosis is aimed preferentially at detection before invasion, once breast cancer 
has no lethal potential before that [104]. In concordance, eighteen European countries set 
regional or national-based screening mammography programs to detect breast cancer in 
a pre-invasive stage [105]. The initial line of diagnosis is based on physical examination, 
which should be done with the patient sitting upright. Inspection of breast anomalies (e.g. 
asymmetry and masses), skin changes and cervical, supraclavicular and axillary lymph 
node basins should be carried out carefully. Following diagnosis, staging and treatment 
decisions are based on diagnostic imaging and core or fine needle biopsies [106]. 
Mammography remains as the main pillar of breast cancer detection, either through 
screening, diagnostic mammograms after discovery of a palpable mass of or other 
symptom of breast disease or follow-up mammograms. As for DCIS, invasive carcinomas 
present as masses, asymmetric entities or calcification punctuations [104, 107, 108]. More 
recently, magnetic resonance imaging (MRI) has also been considered an important tool 
in breast cancer diagnosis and treatment, particularly in cases where mammographic 
evaluation is constrained by aesthetic augmentation, interpretation of inconclusive findings 
in mammography, ultrasonography or assessment of disease extent at the time of 
diagnosis, cases of familial breast cancer associated with BRCA mutations and lobular 
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cancers [106, 107]. Additionally, ultrasound may also be performed as a screening 
method in women at high risk for breast cancer that are not candidates for or do not have 
access to MRI and in cases of suspicion of axillary lymph node involvement. Furthermore, 
the fact that ultrasound allows for real-time imaging makes it an optimal tool during 
interventional procedures [107]. Besides imaging, disease pre-treatment must include a 
complete personal medical history and history of family breast/ovarian cancer, whole 
blood cell (WBC) count, liver and renal function assessment, alkaline phosphatase and 
calcium levels and menopausal status [106]. 
Final diagnosis is made based on the WHO classification [103] and the Tumor-
Node-Metastasis (TNM) combinatory staging system, in order to classify the disease in 
one of five stages (0, I, II, III, IV). The latter includes information on the size of the primary 
tumor, status of regional lymph nodes and the presence or absence of distant metastasis 
at the time of diagnosis, and is essential to clinical decision-making to personalized 
patient therapy. Tumor size is defined based in radiological examination with histological 
confirmation [102]. In node-negatives patients, tumor size is considered the most powerful 
prognostic variable and critical regarding adjuvant treatment decisions [109]. Lymph node 
status is classified according to the extension of lymph node involvement. It is considered 
the most influential prognosis indicator and a critical determinant of adjuvant 
chemotherapy. Lymph node metastasis is associated with tumor size and decreased 
disease-free and overall survival [110, 111]. Presence or absence of distant metastasis at 
the time of diagnosis may be detected by patient symptomatology, clinical examination 
and radiological results [102]. Despite intensive screening programs, 6-10% of patients 
present metastatic disease when diagnosed [112, 113], and 30% of patients with early 
breast cancer will eventually develop distant metastasis [114]. Patients with distant 
metastasis present stage IV disease independently of tumor size and nodal status and a 
5-year survival rate of approximately 22% [115]. Bone, lung, brain and liver are the most 
common breast cancer-metastized organs [116]. However, the histological type of tumor 
and TNM staging are not the only prognostic factors in breast cancer management. The 
classification of invasive breast cancer based on established biomarkers with prognostic 
significance, such as ER, Progesterone Receptor (PR) and HER2 constitutes standard 
practice. They provide additional prognostic and predictive value while aiding in adjuvant 
and chemotherapy regimen decisions [98, 102]. Accuracy and consistency in the 
evaluation of these biomarkers is of mounting importance, in order to guarantee 
comparable results that may follow therapy decision guidelines [106, 117, 118]. 
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The most well-established biomarkers of prognostic, predictive and therapeutic 
importance in breast cancer are presented next. 
- Estrogen Receptor – is a nuclear transcription factor that promotes normal and 
malignant epithelial cell proliferation when stimulated by estrogen through Cyclin D1 
activation [119-121]. ER assessment is routinely done by immunohistochemistry (IHC) 
and evaluated in epithelial cell nuclei [122]. Although there is much debate surrounding 
the decision of the most appropriate threshold for classifying a tumor as ER-positive [123, 
124], it is generally accepted that more than 1% of ER-positive cells is clinically relevant, 
once tumors even with a low expression of ER benefit from hormonal therapy when 
compared with ER-negative tumors [118]. Additionally, patients diagnosed with ER-
positive tumors present higher free and overall survival [125, 126].  Tamoxifen was the 
first anti-estrogenic adjuvant therapy aimed at treating ER-positive tumors [98]. Its effects 
are due to blocking of estrogen stimulation and prevention of essential conformation 
changes needed for the association of coactivators, through ligation to the ligand-binding 
domain of ER [127, 128]. 
- Progesterone Receptor – PR, as ER, is also a nuclear transcription factor that 
stimulates the breast epithelium through progesterone [119, 120, 129]. Given that ER 
regulates PR expression [130, 131] it is thought that PR positivity implies ER positivity. 
However, a small percentage of invasive breast tumors do not have concordant ER and 
PR status [132, 133]. In this respect, it is important to identify these tumors as they might 
also benefit from hormonal therapy [134].  
- HER-2 – HER-2 is a transmembrane tyrosine kinase receptor of the ErbB family, 
whose coding gene (ERBB2) is located on chromosome 17q21 [135-137]. HER-2 
signaling pathway activation leads to increased cell proliferation through the RAS-
mitogen-activated protein kinase (MAPK) pathway and decreased apoptosis through the 
phosphatidylinositol 3’-kinase (PI3K)- AKT- mammalian target of rapamycin (mTOR) 
pathway [138]. HER-2 gene amplification, which occurs in 15-30% of invasive breast 
cancers [98, 102, 139], is strongly correlated with increased HER-2 protein expression. 
HER-2 amplification is a biomarker of poor prognosis once HER-2 positive tumors present 
a more aggressive phenotype, resistance to anti-hormonal and cytotoxic therapies and 
lower overall survival [140-142]. Although HER-2 positivity is related to an adverse 
prognosis, these tumors respond to therapies targeting the HER-2 proteins, such as 
trastuzumab and lapatinib [143, 144]. Although its antitumor effects are not fully 
understood, trastuzumab is thought to act by inhibiting receptor-receptor interaction, HER-
2 cleavage and consequent production of an active truncated HER-2 fragment, increasing 
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receptor destruction by endocytosis and cytotoxicity, and immune activation [145-148]. 
HER-2 status is routinely assessed through immunohistochemistry, and fall into one of 
four categories (0, 1+, 2+, 3+) [117]. Tumors presenting no staining (0) or incomplete 
membrane staining in less than 10% of breast epithelial cells (1+) are considered HER-2 
negative. Invasive breast tumors are considered HER-2 positive (3+) when at least 30% of 
tumor cells display complete membrane staining. Invasive breast cancers with equivocal 
immunohistochemistry results (+2) require testing by in situ hybridization (Silver in situ 
hybridization [SISH]) to confirm gene amplification [117, 149]. 
- Ki-67 – the ki-67 antigen is a non-histone nuclear protein present during all active 
phases of the cell cycle, except G0 and early G1[150]. Given so, it is considered a marker 
of cell proliferation [151, 152]. The Ki-67 score is considered a valuable tool and a 
preferential method for the assessment of the proliferation index instead of counting 
mitoses and represents an independent prognostic parameter of disease-free and overall 
survival [153-155] while being able to predict response to preoperative chemotherapy 
[156]. Although the International Ki-67 in Breast Cancer Working Group has attempted to 
define guidelines for Ki-67 scoring and thresholds [157] its use in clinical practice remains 
limited due to interlaboratory variability [158]. 
- p53 – The p53 gene is located on chromosome 17p13.1 [159] and encodes a 
375 amino acid nuclear phosphoprotein involved in several critical pathways that 
regulates cell cycle arrest, apoptosis, DNA repair and senescence [160-163]. p53 
mutations are the most common mutations in breast carcinomas (approximately 30%) 
[164]. However, its frequency and type of mutation varies greatly between tumor subtypes 
[165, 166]. p53 gene mutations result in an altered protein configuration and prolonged 
half-life which ultimately leads to accumulation of the mutated protein [167-169]. 
Expression of p53 mutant proteins is associated with higher tumor proliferation, early 
disease recurrence, chemotherapy resistance and lower overall survival in node-negative 
breast cancer patients [170-172]. Although nuclear mutant p53 protein accumulation may 
be detected by immunohistochemistry [173], as a surrogate for p53 gene mutations, no 
therapy takes this biomarker status in account [98]. 
 
1.1.2.4.1. Molecular Subtypes 
As reflected by the variable outcome in patients, breast carcinoma heterogeneity is 
well acknowledged. The advent of the genomic era and development of even more 
sensitive technologies for the evaluation of gene alterations and protein expression led to 
Chapter 1. General Introduction – Breast Cancer 
 
 
 
15 
 
a better understanding of the biological basis underlying the observed differences [102, 
174]. The study by Perou and collegues [175] presented as a turning point in breast 
cancer research by demonstrating that the molecular background of these tumors 
reflected its variability. Using microarray technology, they have studied 496 genes 
(nominated “intrinsic gene subset”) in 65 tumors from 42 individuals, and found several 
differences in specific signaling pathways and cellular components [101]. Through 
unsupervised hierarchical cluster analysis they were able to categorize breast tumors into 
biological subgroups that relate to the cell of origin of the tumor: ER-positive tumors 
(Luminal subtype), associated with the expression of typical breast epithelial genes and 
ER-negative tumors (HER-2 and basal/ triple-negative subtypes), expressing 
characteristic genes of basal/myoepithelial cells [175, 176]. A separate group, 
characterized by genes normally expressed in adipose tissue and basal cells, was 
designated as the normal breast subtype, and is thought to represent contamination from 
normal breast tissue [101]. Sorlie and colleagues subsequently expanded the tumor 
cohort and identified subclasses within the ER-positive group [165]. 
These individual molecular subgroups are associated with predicted mutations, 
distinct immunohistochemical profiles and clinical features (Figure 4).  
Figure 4. Most frequently mutated genes in breast cancer molecular subtypes and correlations with 
clinical features. From [177]. 
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According to the aforementioned molecular studies, breast carcinomas can be 
categorized in the following subtypes: 
 ER-positive: 
o Luminal A 
o Luminal B 
 ER-negative: 
o HER-2 
o Basal/ Triple-negative 
o Normal breast-like 
Luminal A 
This subgroup is characterized by hormone receptor positivity (ER and PR), HER-
2 negative status and a low proliferation index and represents of 50-60% of diagnosed 
invasive carcinomas [178]. They are also positive for luminal cytokeratins (CKs), such as 
CKs 8/18 and present upregulation of certain estrogen receptor related genes (GATA3, 
FIXA1 and LIV1) [101]. These tumors are usually well-differentiated, of histological low 
grade and associated with a better prognosis, lower relapse rates and improved overall 
survival in comparison with other subtypes [179-183]. Given that this type of tumors 
presents a high expression of hormone receptors, they are usually treated with endocrine 
therapy or aromatase inhibitors [101, 102]. 
Luminal B 
Luminal B tumors constitute 10-20% of invasive breast carcinomas, and include 
HER-2 positive tumors. In comparison with Luminal A they present a more variable 
degree of hormone receptor positivity and a higher cell proliferation rate, as shown by the 
upregulation of proliferation associated genes, such as CCNB1, MYBL2 and MKI67 [165, 
184]. They are commonly of higher grade and biologically more aggressive, exhibiting a 
worse prognosis with higher chances of relapse than Luminal A tumors [179, 182, 183, 
185]. The inclusion of the Ki-67 labeling index brought significant clinical value to the 
identification of luminal subgroups with poorer prognosis [186]. 
HER-2 
These comprise, approximately, 15% of invasive breast carcinomas and are 
characterized by HER-2 gene amplification or HER2 protein overexpression [187]. 
However, part of HER-2 tumors are not clinically HER-2 positive, with patients being 
treated according to clinical testing results [188]. Additionally, about 40% of tumors in this 
subgroup present p53 mutations [102]. Consequently, HER-2 positive tumors are 
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traditionally associated with an aggressive behavior, multifocal/ multicentric disease and 
extensive nodal involvement [37]. However, the outcome for these tumors has been 
improved due to the introduction of anti-HER-2 agents in chemotherapy regimens, such 
as trastuzumab and lapatinib [189-191]. 
Basal/ Triple-negative 
Basal-like tumors present a distinct phenotype, lacking ER, PR and HER-2 
expression, but displaying overexpression of basal/ myoepithelial cytokeratins (CKs 5/6, 
14 and 17) [192]. Approximately 75% of basal-like tumors exhibit p53 gene mutations 
[165] and increased EGFR expression [101]. They are more frequent in patients with 
BRCA1 mutations and particularly of younger age [193]. Histologically, they are generally 
of high-grade and proliferation index presenting with pushing borders and peritumoral 
lymphocytic infiltrate. Comparing with luminal tumors, triple-negative carcinomas tend to 
have a poorer prognosis, with a significantly shorter relapse-free survival, and highly 
variable response rates to chemotherapy [194]. Treatment for this type of breast tumors 
remains an active area of research, with the introduction of Poly (ADP-ribose) polymerase 
(PARP) inhibitors [195, 196] and anti-angiogenesis agents [197, 198] showing promising 
results. 
Main therapeutic strategies for the management of breast cancer involve surgery, 
chemotherapy and radiotherapy. The type and eventual combination of treatments should 
be decided and provided by a multidisciplinary team specialized in breast cancer [199, 
200].  
 
1.1.3. Breast Tissue Microenvironment 
 
1.1.3.1. Normal Breast Microenvironment 
The mammary gland is constituted by several cellular types that work in synchrony 
by engaging in complex heterotypic communications with neighbour cells and the 
underlying ECM resulting in a coordinated normal development and function. The 
microenvironment surrounds the bilayered epithelial ducts and is composed by 
extracellular matrix and stromal cells, including adipocytes, fibroblasts, myofibroblasts, 
endothelial cells and several types of leukocytes [201-204]. 
The mammary gland is a particular organ once part of its development occurs 
post-natally, more specifically during puberty and pregnancy. Branching morphogenesis 
refers to the complex developmental program that results in ductal infiltration into the 
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surrounding stroma as a response to hormonal stimulus [202].  Several studies brought 
evidence on the fact that cell differentiation and branching architecture is influenced by the 
tissue microenvironment. Cells grown on plastic culture dishes are not able to differentiate 
into epithelial cells capable of milk production while cells cultured in three-dimensional 
reconstituted membrane are [205]. Grafting embryonic salivary gland in adult mammary 
gland tissue or mammary gland epithelium in salivary stroma results in changed epithelial 
architecture [206, 207]. Additionally, mammary gland tumor co-culture with embryonic 
mammary gland stroma leads to tumor differentiation and similar growth to controls [208, 
209]. Moreover, a series of studies have demonstrated that culturing tissues from other 
origin in mammary gland microenvironment causes differentiation into functioning 
mammary epithelial cells organized in ducts [210-212].  
In this context, myoepithelial cells are of particular importance given that they not 
only influence the differentiation, polarity and proliferation of epithelial cells, as they also, 
in combination with the basement membrane, constitute a physical barrier between 
epithelial and stromal cell niches [213, 214]. Signaling through essential basement 
membrane components, such as laminin-322 and collagen IV are essential for branching 
architecture given that genetic knockout (KO) of collagen IV receptor (integrin α2β1) 
subunits blunts branching morphogenesis during pregnancy [215-217]. In turn, laminins 
are essential for tissue-specific differentiation through several mechanisms, such as 
polarity definition or cytoskeleton reorganization [202, 218]. 
Adipocytes constitute one of the microenvironment central players, as they 
contribute to vascularization, epithelial cell proliferation and leukocyte recruitment through 
the release of several growth factors and chemokines, besides providing a frame for 
branching epithelia support [219, 220].  
Fibroblasts are also key elements in the mammary gland tissue microenvironment. 
Its primary function is to participate in the deposition of the collagen-enriched ECM 
underlying the mammary gland ducts [221, 222]. As other tissue microenvironment cell 
types, fibroblasts modulate branching morphogenesis by producing factors that act on 
epithelial cells. Hepatocyte growth factor (HGF) is of particular importance, given that it 
influences epithelial cell proliferation, migration and branching by activating PI3K signaling 
[223-226]. Fibroblast growth factor 2 (FGF2) is also necessary for the branching of 
mammary epithelial cells and has also been shown to promote angiogenesis and 
consequently contribute to a proper oxygen and nutrient supply [227-229].  
In addition to the above mentioned players, several types of leukocytes are also 
necessary for a correct mammary gland development. For example, macrophages that 
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are recruited to the tissue stroma in response to epithelial cell colony stimulating factor-1 
(CSF-1) production, not only clear shed epithelial cells from the ducts during lumen 
formation, but also contribute to the arrangement of fibrillar type I collagen, terminal end 
bud geometry and side branching [230-232]. Similarly, mast cells and eosinophils, 
recruited through eotaxin secretion, also participate in branching morphogenesis [232, 
233]. These studies point to the presence of immune system cells as a normal aspect of a 
functional mammary gland tissue. However, recent studies provide evidence that 
alterations in the number and profile of tumor infiltrating immune cells is associated with 
poor outcome [234]. 
 
 
1.1.3.2. Breast Tumor Microenvironment 
Invasive breast tumors lie in a complex microenvironment composed of an altered 
ECM and several stromal cell populations, most of which increase in cell number during 
the carcinogenic process. In fact, not only cell numbers increase in general as all breast 
tissue cell types present a transformed pattern of gene expression during cancer 
progression  [235-239]. The importance of the microenvironment for invasion has been 
clearly demonstrated in a study by Ma and colleagues revealing that while 5900 genes are 
differentially expressed in epithelial cells between normal and DCIS, only three genes are 
differentially expressed between DCIS and invasive carcinoma [236]. Although 
pathologists have long noticed that certain histopathological characteristics, such as 
leukocyte infiltration or fibrosis present prognostic value, only more recently evidences 
have been provided suggesting that tissue microenvironment heterogeneity contributes to 
the typical features of breast cancer molecular subtypes [240-243]. Actually, changes in 
the tissue microenvironment may occur even earlier that at the DCIS stage, with epithelial 
cell signaling resulting in the secretion of chemokines that cause the accumulation of 
leukocytes, fibroblasts, myofibroblasts, mesenchymal and endothelial cells (Figure 5) 
[235, 236, 244-246]. 
 
Chapter 1. General Introduction – Breast Cancer 
 
 
 
20 
 
 
Figure 5. Alterations in the tissue microenvironment during breast cancer progression. From 
[201]. 
Increased expression of genes associated with invasion and angiogenesis is also 
observed in myoepithelial cells from DCIS, revealing the potential role of these alterations 
in the collapse of the basement membrane. In this sense, myoepithelial cells function as 
“natural tumor supressors” by maintaining the physical basement membrane barrier that is 
lost during invasion [214, 247-249]. Furthermore, the expression genes associated with 
myoepithelial cell differentiation (smooth muscle actin [SMA], oxytocin receptor [OXTR]) is 
also lost or downregulated in DCIS [235].The lack of clonally selected gene mutations in 
myoepithelial and stromal cells suggests that epigenetic mechanisms may be the potential 
drivers of altered expression patterns in these cell populations [203, 250-252].  
Subsequent paracrine, autocrine, juxtacrine, chemokine and heterotypic cellular 
communications govern breast cancer progression, similarly as they guide mammary 
gland morphogenesis [202]. Malignant epithelial cell signaling drives mesenchymal stem 
cell and fibroblast differentiation into myofibroblasts that secrete angiogenesis, 
proliferation and motility promoting growth factors, such as vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF) and transforming growth factor β (TGF-β) 
[253-256].  
The complex interactions between cancer cells and leukocytes are often called of 
“Cancer Immunoediting”, and refers to the fact that although the immune system acts as 
an extrinsic tumor suppressor, it may also be hijacked by the tumor in order to promote its 
development, invasion and metastasis [257, 258]. The process is characterized by an 
elimination, equilibrium and escape phases [259], often referred to as the seventh 
hallmark of cancer [260, 261]. So instead of protecting against carcinogenesis, leukocyte-
driven chronic inflammation promotes tumor proliferation, progression and invasion, 
leading to the release of factors that not only promote the accumulation of genetic 
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mutations in malignant cells as it also recruits other immune cells that might further be 
subverted by the tumor [259, 262, 263]. 
Tumor cells also secrete CSF-1 that attract macrophages to the stroma, than by its 
turn produce multiple angiogenesis and proliferation factors and pave the stroma for 
eventual cancer cell metastasis [264-267]. High macrophage infiltration, particularly in 
areas of necrosis and increased vascular density, is associated with a worse disease-free 
survival prognosis [265, 268, 269]. Macrophage requirements for both tumor progression 
and metastasis have been demonstrated in a transgenic mouse model susceptible to 
mammary cancer with a null mutation in the CSF-1 gene with delayed invasive and 
metastatic carcinoma. Transgenic expression of CSF-1 restored the invasion and 
metastasis process, and was associated with an increased infiltration of macrophages in 
the primary tumor [270]. Macrophage activity is also controlled by other immune system 
cells, with helper T-cells, through interleukin (IL)-4 secretion, playing a particularly 
preponderant role in macrophage polarization towards the tumor-associated macrophage 
(TAM) phenotype [271-274]. In turn, monocytic myeloid derived suppressor cells 
(MDSCs), through an elevated expression of  arginase 1 (Arg1) and inducible nitric oxide 
synthase (iNOS), non-specifically halt T-cell function and proliferation while recruiting 
regulatory T-cells (Tregs) to the tumor microenvironment [275, 276]. Macrophages are 
thought to facilitate tumor progression by two mechanisms:  
 Macrophages promote the migration of breast epithelial cells towards blood 
vessels by a macrophage-tumor cell feedback loop. Malignant breast epithelial 
cells produce CSF-1 that attract colony stimulating factor 1 receptor (CSFR)-
positive macrophages, than in its turn secrete EGF, promoting the proliferation of 
EGFR-positive malignant cells [267, 277, 278]. IL-6 also participates in breast 
cancer cell-MDSC paracrine signaling.  IL-6 expression by malignant breast 
epithelial cells recruits MDSCs to the primary tumor and preferential metastatic 
niches. Conversely, these MDSCs also secrete IL-6 and IL-6 receptor (R) subunit 
α, promoting a positive feedback loop of increased tumor microenvironment IL-6 
[279]. 
 Perivascular macrophages in the invasive front are also in close proximity 
to tumor vessels, and this type of tissue arrangement predicts distant metastasis 
independently of lymph node status [280]. Recently, a study has suggested that 
this process may be triggered by direct physical contact between macrophages 
and tumor cells with consequent formation of RhoA-dependent invadopodia and 
migration [281]. 
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Macrophages probably constitute the tumor microenvironment cell type most 
associated with tumor progression [268, 282, 283]. Mahmoud et al. demonstrated that 
high numbers of cluster of differentiation (CD)68-positive macrophages is associated with 
worst breast cancer-specific survival [282]. On the other hand, overexpression of the 
macrophage migration inhibitory factor (MIF) was associated with an overall better 
prognosis [284]. 
Tregs further contribute to the tumor microenvironment immunosuppression. They 
are selected by the production of reactive oxygen species (ROS) and other inflammatory 
factors that also assist their immunosuppressive activity by disturbing the redox balance of 
other immune cells [285-288]. In primary tumors and lung metastasis the frequency of 
glycan-binding protein galectin-1 (Gal1) positive cells was found to be positively correlated 
with Treg numbers and upregulated by transforming growth factor-β (TGF-β). Stromal and 
tumor cell secreted Gal1 binds to the surface glycoproteins of other immune cells and 
shifts them towards an immunosuppressive phenotype [289]. Other barriers preventing a 
functional lymphocyte cancer cell recognition and tumor elimination include the 
sequestration of tumor antigens and major histocompatibility complex (MHC) molecules 
and loss of costimulatory factors needed for a proper cytotoxic CD8+ T-cell activity [290-
292]. A decreased number of CD4+ Th1 T-cells or their precursors, resulting in a skewing 
of the normal Th1/Th2 ratio and decreased cooperation with cytotoxic CD8+ T-cells may 
also contribute to the failure to suppress tumor growth [293, 294]. B-cell presence is also 
frequent in breast tumors as part of the humoral immune response. Recent studies have 
shown that increased number of B-cells represents an independent indicator for survival 
[295], particularly in triple-negative (TN) breast cancer patients [240]. Additionally, Levy 
and coworkers also demonstrated that the number of natural killer (NK) cells may predict 
recurrence in patients with early stage breast cancer [296]. 
The invasion of epithelial cells by basement membrane breach and the 
accumulation of leukocytes and cancer-associated fibroblasts (CAFs) results in a dramatic 
remodeling of the ECM. The ECM functions as an intermediate in signaling 
communication between the several cell types, and in turn, these cells can regulate both 
its composition and structure [297-299]. ECM remodeling through synthesis, degradation, 
alignment and cross-linking of the matrix [6, 297, 300, 301] affects signaling, potentially 
leading to  tumor cell proliferation and migration, angiogenesis and inflammation [222, 
302-304]. Collagen I alignment and stiffening in the tumor microenvironment not only 
promotes signaling communication between cells as it also sets trails that aid epithelial 
and stromal cells migration [305-308], and represents an independent negative prognostic 
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factor for disease-free survival [309].This ECM rearrangement is promoted by cross-
linking enzymes, such as lysyl oxidase, whose expression is modulated by hypoxia 
inducible factor 1-α (HIF1-α) suggesting an alternative route  by which hypoxia within 
breast tumors may promote metastasis [310-312]. Besides its function as a physical 
scaffold, collagen I also has the ability to modulate numerous signaling pathways [313, 
314], for example, by clustering integrins or regulating  SNAIL1 stability to enhance 
extracellular signal-regulated kinase (ERK) activation [315, 316].  
CAFs form an important cellular component of the tumor microenvironment, arising 
from local fibroblasts and their bone marrow precursors through microenvironment 
production of TGF-β and platelet-derived growth factor (PDGF) [317-319]. Besides 
collagen I, CAFs also secrete muscle actin fibers and proteoglycan that aid in the tumor 
microenvironment reorganization in order to promote tumor outgrowth, growth factor 
storage, and disruption of the healthy surrounding tissue [320, 321]. Hypoxia is also 
directly related to tumor microenvironment rearrangement through CAFs: CAFs secrete 
VEGF and FGF2 as a response to cell membrane mediated Notch receptor-ligand 
signaling in the presence of HIF1-α [322, 323]. New blood vessels represent not only a 
source of oxygen and nutrients but also a path for the recruitment of more CAFs, following 
C-X-C chemokine ligand 12 (CXCL12) secretion into the blood stream. Additionally, CAF 
secretion of CXCL14 into the bloodstream also promotes the recruitment of TAMs, 
MDSCs and Tregs to the tumor microenvironment [323]. On the other hand, Notch 
signaling by CAFs induces p53 expression in normal fibroblasts, facilitating tumor 
infiltration due to an increased antimitogenic response of cells capable of restoring the 
ECM [324]. Along with several factors that influence cancer cell proliferation, motility and 
metastasis, such as insulin growth factor (IGF), matrix metaloproteinase (MMP) 2 or 
chemokine (C-C motif) ligand (CCL)5 [323], CAFs production of FGF2 and fibroblast 
growth factor receptor 2 (FGFR2) promotes an even more aggressive, hormone 
independent, tumor behavior by constitutively activating PRs [325]. 
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1.3. Iron Regulation and the Immune System 
 
Iron is a critical element in life, as a fundamental component of several proteins 
involved in cell cycle regulation and energy production [1, 2]. Iron homeostasis is tightly 
regulated at the systemic and cellular levels to avoid free iron-associated toxicity [3, 4]. 
Current evidence suggests that cells of the immune system participate in the systemic and 
local regulation of iron homeostasis. This is particularly important given the fact that most 
pathogenic agents are iron-dependent and the host must modulate iron availability in 
order to limit its use by microorganisms while assuring the body’s vital iron needs [5-7]. 
On the other hand, there are various ways by which iron levels can fine-tune the immune 
system, evidence supported by the observation that several proteins involved in the 
regulation of iron homeostasis also display immunological properties [8-17]. 
The average human male adult contains, approximately, 4 g of iron, of which, more 
or less, 2.5 g is incorporated in the hemoglobin of erythrocytes. By recycling the iron from 
senescent erythrocytes and delivering it to erythrocyte precursors for hemoglobin 
synthesis macrophages are recognized as the most relevant leukocytes in iron 
homeostasis. They are the main players in iron exchanges to the plasma, by favoring or 
limiting iron export in response to erythropoietic needs or infection/ inflammation [18, 19]. 
The aging alterations in erythrocytes that may lead to macrophage recognition comprise 
Band 3 alterations (which is the most abundant erythrocyte membrane protein) [20, 21], 
phosphatidylserine exposure in the outer cell membrane [22] and increased membrane 
rigidity [23]. Following red blood cells phagocytosis, heme is catabolized inside 
macrophages through the action of heme-oxygenase (HO) – 1, releasing iron into the 
phagosomal lumen that may subsequently be transported to the cytosol by the divalent 
metal transporter (DMT) natural resistance-associated macrophage protein (Nramp) 1 [24-
26] and then exported through ferroportin  (FPN) 1 (Figure 6) [18, 27]. Alternatively, when 
in excess, heme may be directly exported via feline leukemia virus subgroup C receptor 
(FLVCR) into the circulation [28].  
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 Macrophages also regulate plasma iron by sequestering it inside during infection, 
as a response to augmented IL-6 that increases hepcidin production, and then by its turn 
degrades FPN1 at the macrophage cell membrane in an autocrine or paracrine manner 
[30-32].  Given that 90-95% of serum iron is exported by macrophages through the 
process described above, this constitutes an important process to reduce iron availability 
to proliferating pathogens while promoting the activity of innate immune cells [33].  In this 
sense, neutrophils also play a role in decreasing iron availability to invading microbes by 
secreting lactoferrin [34], an iron binder related to transferrin [35], and lipocalin-2, that 
binds siderophores, small organic iron chelators used by pathogens to carry iron from the 
environment [36]. 
However, prolonged activation of these mechanisms may result in the so called 
anemia of inflammation or chronic disease, due to limited iron supply for erythropoietic 
precursors [37-39].  
 
 
 
 
Figure 6. Iron flow in the macrophage. From [29]. 
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Once macrophages are critical to the modulation iron homeostasis, it may be 
expected that, on the other hand, iron levels also have the ability to modulate the 
macrophages’ phenotype. Several attempts have been made in order to classify 
macrophage into subsets. The most successful classification separates macrophages into 
two ‘end-of-the-spectrum’ polarization phenotypes participating in particular immunological 
responses: (1) M1, a subset involved in the responses of type I helper (Th1)  lymphocytes 
to pathogenic agents activated by IFN (Interferon)-γ and Toll-like receptors (TLRs) and 
characterized by a high expression of MHC class II, IL-12 and tumor necrosis factor (TNF) 
α and (2) alternatively-activated or M2, that participate in Th2- type responses, such as 
humoral immunity and wound healing, triggered by cytokines as IL-4 and IL-13 [40, 41]. 
Recent evidences highlight that differences between M1 and M2 macrophages may 
surpass their role in inflammation or scavenging [42] and also reflect the way they handle 
iron.  Functionally, iron retention in M1 macrophages from the reticuloendothelial system 
is a well characterized reaction to inflammation and key to their bacteriostatic role [43, 44]. 
Macrophage iron accumulation, by itself promotes the proinflammatory activity and 
contributes to the maintenance of inflammation, without resolution [45]. Sindrilaru and 
colleagues demonstrated that macrophage iron overloading induced an unrestrained 
proinflammatory M1 activation state, which was perpetuated through the release of TNFα 
and hydroxyl radicals. Treatment of an experimental mouse model with iron-dextran 
resulted in iron accumulation of macrophages presenting a persistent proinflammatory M1 
status within the dermis that could be abrogated by treatment with the iron chelator 
desferrioxamine (DFO) [46]. Conversely, M2 macrophages present an iron exporter 
phenotype, which is consistent with their functional role as scavengers and wound healing 
participants [47, 48]. Once tumor-associated macrophages (TAMs) present a similar 
phenotype to M2 macrophages is expected that this might represent a mechanism of iron 
supply to a growing tumors [42]. In fact, studies by Recalcati and colleagues 
demonstrated that M2-conditioned media enhanced the proliferation of tumoral and non-
tumoral cell lines [47]. 
Studies on lymphocyte traffic and positioning set the foundation for the postulate 
that cells of the adaptive immunological system, which constitute an important circulating 
body component, by binding iron could participate in the regulation of tissue iron toxicity 
by limiting its use by potentially harmful cells, such as bacteria and cancer cells [49-52]. 
Following this idea, De Sousa and co-workers described the first animal model with 
spontaneous iron overload, the β2-microglobulin (β2m) deficient mouse. β2m is a protein 
that associates with the alpha chain of MHC class I molecules and other class-I like 
molecules, such as CD1a or HFE, necessary for its proper expression and stability at the 
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cell surface [53]. As a consequence, mice lacking β2m present a severely decreased cell 
surface expression of MHC-class I molecules, almost no CD8+ T-cells and hepatic 
parenchyma iron overload [54, 55]. Because β2m does not bind the p.C282Y HFE 
mutated form, one could argue that HFE deficiency was the cause of the described 
phenotype, but the fact that treatment with hematopoietic cells attenuated the phenotype 
and deviated the iron overload to Kupffer cells suggested an additional role for leukocytes 
in the systemic regulation of iron overload [55, 56]. Following studies in older mice 
reiterated this idea by demonstrating that β2m deficiency causes higher hepatic iron 
loading, with concurrent steatosis, than HFE deficiency [57]. The fact that the lack of other 
β2m-dependent molecules contributes to systemic iron deregulation and tissue iron 
loading was further established by the demonstration that the pattern of tissue iron loading 
in the HFE-/-RAG1-/- double knockout mice does not recapitulate the phenotype observed 
in β2m-/-Rag1-/- double knockout mice, particularly in what refers to the heart and 
pancreas sparing [59]. Furthermore, δTCR-/- mice, lacking γδ+ intraepithelial lymphocytes 
also present increased liver iron accumulation, in comparison with control mice [60]. 
Besides evidences in animal models, other observations have highlighted that 
alterations of lymphocyte frequencies and/or of its subpopulations are linked to a 
deregulation of iron homeostasis. For a long time it has been known that there is a 
negative correlation between the number of T lymphocytes, particularly CD8+, and the 
severity of iron overload in hereditary Hemochromatosis (HH) patients [61, 62]. T-cell 
phenotypical and functional anomalies, either associated with intrinsic iron overload or the 
HFE p.C282Y variant itself have also been described [9, 63]. Oversaturation of transferrin 
results in increased iron uptake by lymphocytes with a concomitant decrease in their 
proliferation, to levels below to what is observed in the absence of transferrin [64]. 
Conversely, iron deficiency is also critical for T cell differentiation since Transferrin 
Receptor 1 (TFR1) deficiency results in arrest at the triple negative stage (CD3-CD4-CD8-
), while not affecting severely B cell development [65]. Furthermore, in vitro B and T-cell 
proliferation is inhibited by incubation with TFR1 antibodies [66, 67]. Dhur and colleagues  
demonstrated that anemic mice presented not only a lower proportion of Thy-1+ 
splenocytes, CD4+ and CD8+ T-lymphocytes in the spleen, but also decreased 
percentage and absolute number of cell subtypes per spleen. Consistent with this, not 
only iron deficiency is associated with impaired lymphocyte activation after 
phytohematogglutinin, concanavilin A and lipopolysaccharide (LPS) stimulation [68, 69] as 
                                                          
1
 RAG1 – is a gene whose expression is restricted to lymphocytes during developmental stages  and crucial 
for the maturation of B and T-lymphocytes (for review see [58] J.M. Jones, M. Gellert, The taming of a 
transposon: V(D)J recombination and the immune system, Immunol. Rev., 200 (2004) 233-248.) 
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an alteration of the cytokine profile of the activated lymphocytes may occur, with an 
increased expression IFN-γ and lower expression of IL-4 [70]. 
More recently, lymphocytes have also been suggested to attenuate tissue iron 
toxicity by participating in the uptake of non-transferrin bound iron (NTBI). NTBI refers to 
iron associated with low molecular weight complexes, responsible for iron-associated 
oxidative stress and resulting toxicity in iron-overload disorders. Arezes and coworkers 
have demonstrated that T lymphocytes take up and accumulate iron in a similar form to 
hepatocytes, supporting their role as buffers against iron-mediated toxicity [71]. In a 
subsequent study they further cemented this idea by demonstrating that T lymphocyte 
reconstitution, through adoptive transfer in a T lymphocyte-deficient mouse model 
submitted to an iron-rich diet prevented liver and pancreas iron accumulation [72].  
Overall, these observations confirm the proposed influence of the host iron status 
in the behavior of the immune system, particularly in infection situations where iron 
overload may contribute to increased susceptibility to iron-dependent pathogenic agents. 
On the other hand, the immune system, by chronic immune activation may also modulate 
iron homeostasis and perpetuate associated immunopathologies. 
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Despite recent advances in the knowledge of basic biology, diagnosis and 
treatment, breast cancer remains the most common type of cancer in women worldwide, 
with many becoming chemo-resistant, which demands new strategies for disease control. 
In the last decade we have witnessed a growing body of evidence linking the imbalance of 
iron homeostasis with the development, behavior and progression of neoplastic diseases. 
Particularly, in breast cancer, current data suggests that an iron regulatory gene signature 
associated with minimized epithelial intracellular iron content may predict a favorable 
outcome, particularly in ER+ patients treated with tamoxifen monotherapy.  
In spite of the established impact of genetic and epigenetic changes in breast 
epithelial cells in breast cancer progression, it is now well accepted that these are not 
sufficient for the acquisition of a fully malignant phenotype. In this respect, gaining insight 
about the mechanisms by which the cells of the microenvironment promote tumorigenesis 
is of vital importance. The potential role of cells that take part in systemic iron regulation, 
such as lymphocytes and macrophages, has not been established in the context of local 
iron homeostasis in the breast. 
The main goal of this doctoral thesis was to characterize the iron-associated 
phenotype of breast epithelial cells, lymphocytes and macrophages in different stages of 
breast cancer progression. For that purpose, and making use of a series of breast 
aesthetic reduction specimens, DCIS and IDC, the following studies were performed to 
assess specific objectives: 
I. Analyze the iron-related phenotype of epithelial cells, lymphocytes and 
macrophages in human normal breast and carcinoma samples. 
Using antibodies against Hepcidin, FPN1, TFR1 and Ferritin (FT) the purpose was 
to characterize the iron-utilization or iron-donor phenotypes of epithelial cells, 
lymphocytes and macrophages from primary breast cancer samples, and 
metastized and non-metastized lymph nodes. The potential association between 
the expression of these iron-related proteins and classical clinicopathological 
markers of breast cancer behavior and progression was also a specific aim of this 
study. 
II. Evaluate the role of the chemokine CCL2 as a potential modulator of tissue 
iron status in breast cancer. 
We aimed at testing if the expression of CCL2 in breast epithelial cells and 
macrophages could be a modulator of tissue iron deposition and of the iron-
exporter phenotype observed in lymphocytes and macrophages. Moreover, the 
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association between CCL2 and the clinicopathological markers of breast cancer 
behavior and progression was also assessed. 
III. Test the influence of the HFE variants, p.C282Y and p.H63D, on the 
expression of iron-related proteins. 
The previously established expression of the iron-related proteins was further 
evaluated in relation to the presence of HFE variants, in order to test the 
hypothesis that these are modulators of the expression of iron-related proteins in 
breast tissue. 
IV. Analyze the iron-related phenotype of epithelial cells, lymphocytes and 
macrophages in benign lesions and mammary gland tumors from cats and 
dogs. 
Using the same approach as for objective I. we aimed at verifying if the cat and 
dog are good animal models for human breast carcinogenesis, i.e., if they 
recapitulate or not the variations observed in the expression of iron-related 
proteins in human breast cancer. 
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Abstract 
Tumor microenvironment is pivotal for neoplastic progression. Recent studies 
reported that stromal inflammatory cells may supply iron to tumors. Recruitment of 
inflammatory leukocytes into the tumor milieu involves chemokines, such as CCL2. Our 
aim was to understand whether CCL2 expression, in the breast cancer model, could be 
related to tissue iron status. 
A total of 21 normal samples, 27 ductal carcinomas in situ (DCIS) and 35 invasive 
ductal carcinomas (IDC) were used for tissue microarray construction. DAB-enhanced 
Perls’ staining and immunohistochemistry for CCL2, ferroportin 1 (FPN1), CD68, CD4, 
CD8 and FoxP3 were performed. The common HFE variants (p.C282Y and p.H63D) were 
characterized by PCR-RFLP.  
Comparing with normal samples, a higher proportion of carcinomas presented iron 
deposition. Epithelial CCL2 expression was associated with the infiltration of CCL2-
positive macrophages, CD4-positive lymphocytes and total lymphocyte infiltration. The 
median epithelial CCL2 expression was higher in the presence of iron in stromal 
inflammatory cells and its expression was associated with FPN1 expression in 
lymphocytes. No associations were found between HFE variants and iron deposition or 
CCL2 expression. Moreover, epithelial CCL2 expression was significantly associated with 
the estrogen-receptor negative status. 
Overall this study provides further evidences supporting the notion that tumor-
infiltrating inflammatory cells display deregulated iron homeostasis, possibly favoring the 
supply of iron to breast tumor cells. Associations found between epithelial CCL2 
expression and infiltration of stromal inflammatory cells suggest the existence of a 
paracrine signaling pathway where CCL2 may play an indirect role regulating tumor iron 
nutrition and progression.  
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Introduction 
Iron is an essential microelement, vital for a variety of biological and cellular 
processes (1). However, iron is also toxic, due to its participation in the formation of 
mutagenic hydroxyl radicals (2), suppression of the host immune response (3) and by 
acting as a limiting nutrient for proliferating tumor cells (4). Epidemiological, experimental 
and clinical evidences support the hypothesis that iron is strongly associated with breast 
cancer initiation and progression (5-7). Results from several studies provide evidence that 
tumor cells behave as iron deficient and are able to undermine the tightly physiological 
process of iron regulation, by increasing iron acquisition and retention, independently of its 
intracellular iron levels (1, 8). Upregulation of the transferrin receptor 1 (9), production of 
transferrin  (10) and downregulation of ferroportin 1 (FPN1) (8, 11) have been reported in 
breast cancer as signs of deregulation of iron homeostasis. 
Accumulating evidences are bringing some new insight on the role of tumor-
associated inflammatory cells. A multitude of studies reported that malignant cells require 
an appropriate support structure to successfully acquire a full malignant potential (12, 13). 
Tumor-associated macrophages constitute up to 50% of the tumor mass and contribute to 
each stage of tumor progression, by promoting matrix remodeling, tumor cell invasion, 
neovascularization and metastasis (14). The M1/M2 dichotomy is frequently used to 
characterize these cells and polarization is dependent on specific stimuli (15). 
Macrophages are also fundamental cells for regulation of iron homeostasis (16) and 
polarization can have important effects on iron metabolism (17). Conversely, iron can 
directly influence macrophage polarization (17).  
In a recent study performed by Marques and colleagues, iron-profiles of breast 
cancer tumor-associated cells were analyzed (18). Data obtained from this study suggest 
lymphocytes and macrophages exhibit an “iron-donor” phenotype, characterized by 
increased FPN1 and ferritin expression in carcinomas comparing to their normal 
counterparts, reinforcing the role of these immune cells as potential iron suppliers.  
One of the chemokines known to polarize macrophages into an M2-like phenotype 
is CCL2 (19). CCL2 (chemokine [(C-C motif)] ligand 2) is known to play a role in leukocyte 
recruitment into the tumor microenvironment and is one of the most studied chemotactic 
cytokines in the context of tumor progression, particularly in breast cancer (20). The 
modulation of CCL2 expression by cellular iron status was already demonstrated by 
Mitchell and colleagues, in a study using neuroblastoma and astrocytoma cells. 
Regardless of the malignant cell type and HFE genotype, CCL2 secretion was influenced 
by iron status, with the exception of cells expressing the p.C282Y HFE variant. In the non-
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malignant cell line also included in this study, this HFE variant did not appear to alter the 
impact of cellular iron status on CCL2 expression (21). In other studies, not related to 
neoplastic disease, iron supplementation or chelation also influenced CCL2 protein levels 
(22-25). 
Given the recent evidences suggesting that tumor-associated macrophages and 
lymphocytes are involved in iron deregulation, and the key role of CCL2 as a macrophage 
chemoattractant, we investigated whether CCL2 expression is associated with tissue iron 
status in breast cancer. We analyzed CCL2 expression, assessed the local iron deposition 
and the expression of FPN1 in stromal inflammatory cells and looked for correlations 
between CCL2 expression and iron profiles in epithelial and stromal inflammatory cells, 
especially with proteins known to be deregulated during neoplastic progression. In 
addition, we analyzed whether CCL2 expression could be associated with the presence of 
the HFE allele variants and with clinical-pathological parameters. 
 
Materials and Methods 
Breast Tissue samples 
This study was approved by the Ethics Committee of the Porto Hospital Centre, 
Portugal. A total of 83 samples, consisting of 35 invasive ductal carcinomas (IDC), 27 
ductal carcinomas in situ (DCIS) and 21 aesthetic reduction mammoplasty samples were 
selected. Corresponding formalin-fixed, paraffin-embedded (FFPE) tissue blocks and 
hematoxylin-eosin (H&E) slides were collected from the archives of the same Pathology 
Service (Porto). Selected tumor samples were representative of primary breast tumors, 
collected from women diagnosed between 2004 and 2009, not previously subjected to 
neoadjuvant treatments.  
Clinical information 
Clinical and pathological parameters were retrieved from interin pathological 
reports. These included histological diagnosis, tumor size, lymph node involvement, 
estrogen (ER) and progesterone receptors (PR) and human epidermal growth factor 
receptor 2 status (HER-2). Peripheral white blood cell (WBC) count was also available.  
Tissue microarray construction 
H&E slides corresponding to the original FFPE blocks were analyzed by a 
pathologist, in order to select normal, in situ and invasive areas. The selected area was 
removed from the donor block and placed into the recipient block, following a previously 
designed map. Normal liver and lymph node tissues were also inserted, as internal 
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controls for immunostainings. A total of 452 cores were used for tissue microarray 
construction, out of which 297 were available for further pathological analysis. TMA blocks 
were cut in 2 μm sections and H&E staining was performed. These slides were used for 
the pathologist to classify the cores, without knowledge of the type of donor sample. A 
designation of “Normal in DCIS” or “Normal in IDC” was attributed to the cores with non-
neoplastic tissue, retrieved from DCIS samples or IDC samples, respectively. Moreover, 
designation of “pure DCIS” or “pure IDC” was attributed to cores representative of the 
original sample.  A total of 21 normal, 17 normal in DCIS, 27 pure DCIS, 28 normal in IDC 
and 35 pure IDC samples were analyzed. 
DAB-enhanced Perls’ Prussian Blue staining 
In order to assess hemosiderin deposition, DAB-enhanced Perls’ Prussian Blue 
was performed, as described in (26). TMA blocks were cut in 4 μm sections and mounted 
in adhesive slides coated with 3-Aminopropyltriethoxysilane (APES) (A3648, Sigma-
Aldrich, St. Louis, MO, USA). Slides were stained with 1% potassium cyanide in distilled 
water, for 40 minutes, and washed in distilled water. Samples were treated with methanol 
containing 0.01M NaN3 and 0.3% H2O2 for 75 minutes and washed with PBS. For the 
intensification reaction, slides were incubated with a solution containing 0.025% 3.3' – 
Diaminobenzidine-tetrahydrochloride (3.3’-DAB-4HCl) and 0.005% H2O2 in PBS, for 40 
minutes. The reaction was stopped by rinsing in distilled water and tissues were 
counterstained with nuclear red  (Merck Millipore, Darmstadt, Germany). A negative 
control was used by omitting the incubation with potassium ferrocyanide. Degradation of 
H2O2 by potassium ferrocyanide, together with the addition of DAB, leads to the formation 
of a dark-brown coloration due to the polymerization of the chromogen (27).  
Immunohistochemistry 
CCL2, CD68 (macrophages), CD4 (T-helper lymphocytes), CD8 (cytotoxic T 
lymphocytes) and FoxP3 (regulatory T lymphocytes) immunohistochemistry was 
performed on TMA sections. Mouse monoclonal anti-human CCL2 (ab9858, 1:25, Abcam, 
Cambridge, United Kingdom), mouse monoclonal anti-human CD68 (clone KP-1, 1:2000, 
Cell Marque Corporation, California, USA,), polyclonal anti-human CD4 (clone H-370; 
1:250; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), monoclonal anti-human 
CD8 (clone C8/144B; 1:100; Cell Marque, Rocklin, California) and monoclonal anti-human 
FoxP3 (clone 236A/E7; 1:200; eBioscience, San Diego, USA) antibodies were used. 
FPN1 immunohistochemistry was performed as previously described (18). Antigen 
retrieval was performed using Dako Target Retrieval Solution (Agilent Technologies, 
Denmark), at 10% in distilled water, in a water bath at 100ºC, for 25 minutes. 
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Immunostaining was performed using the Novocastra Novolink Detection System (Leica 
Systems). All antibodies were used in single immunohistochemistry procedures, except 
for CD4 and FoxP3, which were simultaneously incubated in the same slide. Revelation 
was performed using DAB and counterstained with Mayer’s hemalum solution (Merck 
Millipore, Billerica, MA, USA).  Antibody dilutions were determined in tissue positive 
controls and negative controls were included by replacing the primary antibody with an 
antibody of the same immunoglobulin isotype.  
Immunostaining analysis 
 For the evaluation of CCL2 and FPN1 staining in epithelial and stromal 
inflammatory cells, a semi-quantitative method was used. The following cut-off values 
were established for the intensity: score 0 = no staining; 1 = weak; 2 = moderate and 3 = 
strong staining. For the area stained the following cut-off values were considered: score 0 
= 0%; 1 = 1-10%; 2 = 11-20%; 3 = 21-35%; 4 = 36-50% and 5 = >50%. The final score 
was obtained by multiplying the area and the intensity scores. CCL2+ and CD68+ 
macrophages, plus CD4+, CD8+ and CD4+FoxP3+ T-lymphocytes were counted in 5 high 
power fields (HPF), which are representative 400× fields in each spot. The values 
obtained for each antibody, from the 5 HPFs, were added in order to obtain the total cell 
count. Cores from the same donor tissue diagnosed with the same histological type were 
grouped and their mean score calculated. 
Genotyping  
Genomic DNA was extracted from FFPE sections using the Ultraprep Tissue DNA 
kit (AHN Biotechnologie, Nordhausen, Germany). PCR was carried out in 15.5μL reaction 
volumes, containing 2μL of the genomic DNA template, 7.5μL of MasterMix DNA 
polymerase, 1μL of Q-solution (both from Qiagen Multiplex PCR kit, Valencia, CA, USA) 
and 1μL of each of forward and reverse primers. For the detection of the C282Y 
polymorphism the following primers were used: 5'-
CAAGTGCCTCCTTTGGTGAAGGTGACACAT-3' as the forward primer and 5’-
CTCAGGCACTCCTCTCAACC-3’ as the reverse primer (Metabion, Steinkirchen, 
Germany). These primers amplify a fragment with 343 bp and RsaI was the endonuclease 
used. For the HFE H63D polymorphism, the following forward and reverse primers’ 
sequences were used: 5’-ACATGGTTAAGGCCTGTTGC-3’ and 5’-
GCCACATCTGGCTTAAAATT-3’ (Metabion, Steinkirchen, Germany). These primers 
amplify a fragment with 294 bp and the endonuclease MboI was used for restriction. 
These primers were chosen according to the work of Feder et al. (28). A “hotstart” 
polymerase enzyme was used, so an initial step of 95ºC, for 15 minutes, was executed. 
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Following this, 36 cycles of denaturation at 94ºC for 30 seconds, annealing at 58ºC for 90 
seconds and extension at 72ºC for 90 seconds were performed. Reaction was extended 
at the end for 10 minutes at 72ºC. The same PCR program was used for both HFE 
variants. 
Statistical analysis 
Data was analyzed with IBM SPSS Statistics 18.0 (SPSS Inc., IBM, Chicago, IL, 
USA). Graphically, results are presented showing median values and more or less 95% CI 
(confidence intervals). Pearson’s Chi-Square was used to evaluate the differences 
between categorical variables. Sample distributions were compared using Kruskal-Wallis 
or Mann-Whitney tests. The first one was used to determine statistical significance when 2 
data sets were compared and Kruskal-Wallis test to compare between 3 set of data. The 
Dunn-Bonferroni post hoc method was performed following a significant Kruskal-Wallis 
test to determine the statistical significant between 2 specific groups. The Spearman’s 
rank correlation coefficient was used to evaluate the relationship between variables. 
Statistical significance was accepted at p<0.05.   
 
Results 
Tissue iron deposition demonstrated by DAB-enhanced Perls’ 
The presence of hemosiderin deposition was assessed in epithelial and in stromal 
inflammatory cells by the DAB-enhanced Perls’ method. When present, hemosiderin 
deposits were found in the cytoplasm (Figure 1a and Figure 1b).  
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Figure 1. Evidence of hemosiderin deposition in a DCIS lesion (a) and in an IDC lesion (b). DAB-
enhanced Perls’ staining of breast tumors, particularly in epithelial (a) and stromal inflammatory cells 
(b). Original magnification of 200X (a and b) and 400X (inset). 
 
Tissue iron deposition was evaluated by assessing the percentage of cases 
diagnosed within the same lesion presenting iron deposits in epithelial or stromal 
inflammatory cells. Regarding pure lesions, the presence of hemosiderin deposits in 
epithelial and stromal inflammatory cells was more evident in carcinomas than in normal 
tissue (Figure 2). Moreover, statistically significant differences were found for iron 
deposition in stromal inflammatory cells, between normal and pure DCIS (p=0.011) and 
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normal and pure IDC (p=0.001) (Figure 2). The presence of hemosiderin deposits in 
epithelial and in stromal inflammatory cells was more evident in non-neoplastic tissue 
adjacent to carcinomas than in normal tissue from reduction mammoplasty samples 
(p=0.037) (Figure 3). Differences in the percentage of samples presenting iron deposition 
in stromal inflammatory cells were statistically significant when comparing normal tissue to 
normal tissue adjacent to IDC lesions (p=0.011) (Figure 3).   
 
Figure 2. Presence of hemosiderin deposition in pure lesions of the breast, in epithelial (grey) and in 
stromal inflammatory cells (black). Chi-square test for iron deposition in stromal inflammatory cells in 
pure lesions: between normal and pure DCIS p=0.011; between normal and pure IDC p=0.001 (*p< 0.05, 
**p< 0.01, ***p< 0.001). Abbreviations: EC, epithelial cells; SIC, stromal inflammatory cells; DCIS, 
ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
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Figure 3. Presence of hemosiderin deposition in the tissue adjacent to breast lesions, in epithelial 
(grey) and in stromal inflammatory cells (black). Chi-square test for iron deposition in stromal 
inflammatory cells: p=0.011 (*p< 0.05, **p< 0.01, ***p< 0.001). Abbreviations: EC, epithelial cells; SIC, 
stromal inflammatory cells; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
Association of CCL2 expression in epithelial and stromal inflammatory cells with 
malignancy 
CCL2 has been implicated in breast cancer progression, mainly because of its role 
as a leukocyte chemoattractant. Comparing with normal tissue, CCL2 immunostaining 
was higher in tumor samples. Expression of CCL2 in epithelial cells was positively 
correlated with malignancy (n=80; p=0.007; r= 0.299), as assessed by the Spearman’s 
rank correlation test. Kruskal-Wallis test was performed and revealed differences in the 
epithelial CCL2 expression between sub-groups of pure lesions (p=0.022). Dunn-
Bonferroni correction showed that statistical significance was only reached when 
comparing normal to pure IDC lesions (p=0.017) (Figure 4a). Increased expression of 
CCL2 was already evident in the non-neoplastic tissue adjacent to carcinomas, but we 
found no statistically significant differences in epithelial CCL2 expression when comparing 
normal tissue from reduction mammoplasties to non-neoplastic tissue adjacent to 
carcinomas (p=0.067)) (Figure 4b). 
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Figure 4. Median epithelial CCL2 expression in (a) pure lesions of the breast and (b) in non-neoplastic 
tissue adjacent to breast lesions. (a) Dunn-Bonferroni test: between normal and pure IDC lesions 
p=0.007. Error bars: 95% CI. (*p< 0.05, **p< 0.01, ***p< 0.001). Abbreviations: DCIS, ductal carcinoma in 
situ; IDC, invasive ductal carcinoma. 
 
Local infiltration of CCL2-positive macrophages was also analyzed by 
immunohistochemistry. Total macrophage count presenting CCL2 immunostaining was 
strikingly higher in pure DCIS lesions and was also positively associated with increased 
malignancy (n=74; p=0.004; r= 0.335) (Figure 5a). Kruskal-Wallis test revealed statistically 
significant differences between sub-groups of pure lesions (p<0.001). The Dunn-
Bonferroni test revealed that differences in normal samples comparing with pure DCIS 
and normal comparing with pure IDC samples were statistically significant (Figure 5a). 
Kruskal-Wallis test revealed no statistical differences in the infiltration of CCL2-positive 
macrophages between normal tissue from aesthetic reduction mammoplasties and non-
neoplastic tissue adjacent to carcinomas (p=0.069) (Figure 5b).  
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Figure 5. Infiltration of CCL2-positive macrophages in (a) pure lesions and (b) in non-neoplastic tissue 
adjacent to breast lesions. (a) Dunn-Bonferroni test: between normal and pure DCIS p<0.001; between 
normal and pure IDC p=0.001. Error bars: 95% CI. (*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent 
group) Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
Association of total macrophage infiltration with malignancy 
CD68 immunohistochemistry was performed to facilitate macrophage counting and 
assess total macrophage infiltration. Macrophage infiltration was more evident in 
carcinomas than in normal mastectomy samples. According to the Spearman’s test, the 
number of macrophages was positively associated with malignancy (n=75; p<0.001; 
r=0.630). Kruskal-Wallis test revealed statistically significant differences between sub-
groups of pure lesions (p<0.001). Dunn-Bonferroni test revealed significant differences 
when comparing normal to pure DCIS (p=0.003) and normal comparing to pure IDC 
(p<0.001). In the hypothetically normal tissue adjacent to carcinomas, the Kruskal-Wallis 
test revealed no statistically significant differences between sub-groups of lesions 
(p=0.099).  
Association of CCL2 expression with macrophage and lymphocyte infiltration 
Epithelial CCL2 expression was not correlated with total macrophage infiltration 
(n=75; p=0.609), but was associated with infiltration of CCL2+ macrophages (n=73; 
p=0.022). Infiltration of CCL2+ macrophages was positively associated with total 
macrophage infiltration (n=73; p<0.001; r=0.488). On the other hand, expression of this 
chemokine was positively correlated with the infiltration of CD4+ lymphocytes into the 
tumor microenvironment (n=67; p=0.019; r=0.286) and with total count of lymphocytes 
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(n=67; p=0.025; r=0.273). Infiltration of cytotoxic T-lymphocytes (CD8) or regulatory T 
cells (CD4/FoxP3) was not correlated with CCL2 epithelial expression or with the 
infiltration of CCL2+ macrophages. 
Expression of FPN1 in stromal inflammatory cells 
We next analyzed FPN1 expression, by immunohistochemistry, in stromal 
inflammatory cells. Regarding macrophages, considering pure lesions, FPN1 was higher 
in pure DCIS lesions. Kruskal-Wallis test was performed and statistically significant 
differences were found between sub-groups of pure lesions (p<0.001). According to the 
Dunn-Bonferroni correction, differences in FPN1 expression in macrophages were 
statistically significant when comparing normal samples to pure DCIS (p=0.001) and pure 
DCIS to pure IDC (p<0.001). When considering the non-neoplastic tissue adjacent to 
carcinomas, differences in FPN1 expression in macrophages were statistically significant 
(p=0.009). According to the Dunn-Bonferroni test, differences between sub-groups of 
lesions were only statistically significant when comparing normal tissue to non-neoplastic 
tissue adjacent to DCIS lesions (p=0.007). In lymphocytes, according to the Kruskal-Wallis 
test differences between sub-groups of pure lesions were statistically significant 
(p=0.011). Dunn-Bonferroni correction revealed differences statistically significant when 
comparing normal samples to pure IDC (p=0.016). In addition, no statistically significant 
differences were found between normal tissue from reduction mammoplasties and non-
neoplastic tissue adjacent to carcinomas, regarding FPN1 expression in lymphocytes 
(p=0.079). 
Association of CCL2 expression and tissue iron deposition 
We next determined whether CCL2 expression was associated with tissue iron 
status and explored this association. Samples presenting iron deposition in epithelial cells 
showed similar median CCL2 levels to samples without iron deposits. On the other hand, 
epithelial CCL2 expression was associated with iron deposition in stromal inflammatory 
cells (n=69; p=0.001). In the presence of hemosiderin deposits in lymphocytes and 
macrophages, median CCL2 expression in epithelial cells was superior, comparing to 
samples without iron deposition in stromal inflammatory cells.  
Association of CCL2 and FPN1 expression  
The remarkable increase in FPN1 expression in stromal inflammatory cells, in 
carcinomas, and the association obtained between CCL2 expression and iron status, led 
us to analyze whether CCL2 and FPN1 expression could be correlated. Epithelial CCL2 
expression was correlated with FPN1 expression in lymphocytes (n=55; p=0.001; 
r=0.428), but not in macrophages.  
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Association of FPN1 expression with tissue iron status 
Next, we analyzed whether the increased FPN1 expression observed previously 
was due to increased iron levels in stromal inflammatory cells. In macrophages and 
lymphocytes, FPN1 expression was not correlated with iron deposition in stromal 
inflammatory cells.  
Influence of HFE variants in CCL2 expression 
Considering that polymorphisms in the HFE gene are relatively common in the 
general population and given the fact that they were described as modifiers of CCL2 
expression, we next analyzed whether the presence of p.C282Y and p.H63D variants 
could influence the expression of this chemokine. Of the 83 samples studied, genotyping 
of the p.C282Y variant was possible for 76 individuals, of which 9 were heterozygous and 
the remaining homozygous wild type. Genotyping for the p.H63D variant was possible for 
69 individuals, of which 36 were homozygous wild type, 27 were heterozygous and 2 were 
homozygous for the variant. In this study, given the low frequency of individuals with the 
p.C282Y variant, further statistical tests were not performed. CCL2 expression in epithelial 
cells was not associated with the HFE H63D variant.  
Correlation of CCL2 expression with clinico-pathological parameters 
We next determined whether epithelial CCL2 expression was associated with 
clinical-pathological parameters of breast cancer behavior and prognosis. CCL2 
expression was significantly higher in epithelial cells of ER-negative DCIS cases (n=25; 
p=0.011). In invasive ductal carcinoma samples, CCL2 expression in epithelial cells was 
not associated with the estrogen receptor status. Statistical analysis did not show 
significant associations between epithelial CCL2 expression and classical prognostic 
parameters, such as tumor size (n=35; p=0.249), molecular subtype (n=55; p=0.215) and 
lymph node involvement (n=35; p=0.817).  
 
Discussion 
With the present study, we shed new light into the role of stromal inflammatory 
cells and CCL2, one of the chemokines responsible for their attraction into the tumor 
microenvironment. A large body of evidence points to the fact that cells in the tumor 
microenvironment also undergo alterations in response to stimuli sent by epithelial cells, 
consequently contributing to tumor progression (29). Furthermore, data from different 
fields of research suggest that in current cancer biology, it should be virtually impossible 
to address the importance of the tumor milieu without considering the nutritional role of 
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iron (30). Recent work performed by our group demonstrated that tumor infiltrating 
macrophages and lymphocytes display an “iron-donor” phenotype, which suggests that 
they may act as an iron reservoir, hypothetically contributing to tumor nutrition (18). 
Results herein described corroborate the hypothesis that stromal inflammatory cells may 
play a fundamental role in tumor progression, demonstrated by the increased expression 
of FPN1 in these cells independently of iron levels. In this study, a higher percentage of 
breast cancer samples presented hemosiderin deposits in epithelial tumor cells, in 
comparison to normal samples. Due to their incessant proliferation, neoplastic cells have 
high nutritional requirements, which results in homeostatic deregulation favoring higher 
intracellular concentrations of iron (9). As first described by Pinnix and colleagues, the 
deregulation of the ferroportin/hepcidin axis may be central in breast tumor progression 
(8). Moreover, Chen and co-workers, validating a previous work by Zhang and co-workers 
(11), reported that FPN1 reduction in epithelial cells was associated with increased 
intracellular iron levels, which suggests that actively proliferating neoplastic cells have a 
constant supply of iron, necessary for metabolic reactions (31). Remarkably, we detected 
increased iron deposition not only in the established malignant lesions, but also in the 
hypothetically normal tissue adjacent to the representative breast lesion. These results 
suggest that the non-neoplastic tissue adjacent to carcinomas already present alterations 
that predispose the microenvironment to acquire more iron for metabolic processes. So, 
iron deregulation may occur previously to the establishment of lesions and is already 
present in non-malignant lesions, such as hyperplasias, therefore facilitating epithelial cell 
proliferation, dysplasia and the potential accumulation of mutations (1).   
Our results also demonstrate that increased iron deposition is not limited to 
epithelial cells and that lymphocytes and/or macrophages, especially in carcinoma 
samples, also present iron accumulation. Lymphocytes are capable of uptaking non-
transferrin-bound iron, as demonstrated in a recent study by Pinto and colleagues (32). 
Macrophages are also specialized cells in handling iron (16) and the regulation of iron 
homeostasis performed by these cells is possibly not restricted to the systemic level, but 
also occurs locally. In response to the presence of heme, as a consequence of 
erythrophagocytosis, FPN1 expression in macrophages is upregulated, independently of 
hepcidin (33). Based on several evidences, de Sousa hypothesized that in situations of 
increased blood flow and in the presence of heme, namely in angiogenesis, macrophages 
mimic this process, by delivering iron to facilitate tumor growth (30). As suggested by de 
Sousa (30) and supported by the studies previously presented, circulating immune cells 
may have a surveillance role in controlling potential iron toxicity (34). Tumor-associated 
macrophages, characterized as M2-like macrophages, act as iron-deficient and are 
Chapter 4. CCL2 Expression in Breast Ductal Carcinomas: a Novel Modulator of Local Iron Homeostasis? 
 
104 
 
characterized by higher FPN1 expression. Recalcati and colleagues reported that M2 
macrophages are capable of exporting iron in vitro, which may exacerbate the neoplastic 
disease by supplying iron to actively proliferating tumor cells (35). As also reported in the 
work here presented, increased FPN1 expression in lymphocytes and macrophages, 
particularly in the “normal” to ductal carcinoma in situ transition, may reinforce the iron 
exporting phenotype suggested for stromal inflammatory cells.  
Chemokines are best known for their ability to induce cell migration and 
significantly contribute to cancer progression and metastasis (36). Taking this into 
consideration, expression of CCL2 in epithelial and stromal inflammatory cells was 
analyzed by immunohistochemistry. In this study, an increased expression of CCL2 in 
epithelial and stromal inflammatory cells was observed with increasing malignancy.  
Mantovani was the first to report that tumor-derived chemokines could be 
responsible for the attraction of monocytes into the tumor nest, where they could enhance 
tumor progression, by supplying angiogenic factors and promoting growth (37). The 
evidence of a significant association between the expression of epithelial CCL2 and the 
infiltration of CCL2-positive macrophages consolidates the idea of a paracrine signaling 
pathway. Several authors demonstrated the existence of this pathway, in which tumor 
cells produce CCL2, responsible for the egress of CCR2-positive monocytes from the 
bone marrow into the tumor area (38). Tissue macrophages also secrete CCL2, recruiting 
more macrophages, as demonstrated by Fujimoto and colleagues (39). Our study 
demonstrates that the infiltration of CCL2-positive macrophages was positively associated 
with total macrophage infiltration. These results suggest that, as proposed by Fujimoto 
and colleagues, CCL2 secreted by macrophages, attracted by tumor secreted CCL2, is 
accountable for the attraction of macrophages from the bone marrow into the breast tumor 
milieu (39).  
Epithelial expression of CCL2 was also positively correlated with the infiltration of 
CD4+ lymphocytes and total lymphocyte infiltration. Although CCL2 is considered to be a 
monocyte chemoattractant, some studies report that this chemokine may also be an 
agonist for lymphocytes. Studies performed by Owen and colleagues reported co-
localization of the CCR2, the CCL2 receptor, and the pan T cell marker CD3 (40). 
Moreover, results from a study using a melanoma cell line incubated into mice, suggest 
that the migration of lymphocytes is dependent on CCL2 produced by tumor cells (41). 
The influence of iron status in CCL2 expression was already demonstrated by 
Mitchell and colleagues (21) and in other studies not related to neoplastic disease (22-25). 
In our study, the presence of iron deposits in stromal inflammatory cells was positively 
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associated with increased epithelial CCL2 expression. This significant association 
suggests iron as a putative driving force to enhance CCL2 expression in the breast tumor 
environment.  
FPN1 expression can be regulated at the transcriptional (by iron deficiency 
hypoxia, heme and inflammatory cytokines), post-transcriptional (by the IRP-IRE system) 
or post-translational levels (by hepcidin) (42). Delaby and colleagues demonstrated that 
FPN1 expression in macrophages and lymphocytes was mainly regulated by iron levels, 
putatively by the IRP-IRE system (33). In our study FPN1 post-transcription is not 
regulated by iron levels, suggesting the existence of an alternative signal in the regulation 
of the iron exporter in breast cancer. Furthermore, expression of FPN1 in lymphocytes, 
which had been shown to be independent from the iron deposition in stromal inflammatory 
cells or hepcidin regulation (data not shown), was significantly correlated with CCL2 
expression in epithelial cells.  
These results led us to propose the existence of a mechanism, in which epithelial 
cells produce CCL2, whose expression may be putatively enhanced by increased iron 
deposition in stromal inflammatory cells, resulting in the attraction of circulating 
macrophages and lymphocytes into the tumor site. When these immune cells arrive to the 
local, FPN1 expression is upregulated, at least partially by the expression of CCL2, and 
iron is supplied to malignant cells. CCR2-positive macrophages, attracted to the tumor 
milieu, are responsible for the production of more CCL2, resulting in more infiltrating 
stromal inflammatory cells (Figure 6). In conclusion, CCL2 may also play a role in 
regulating tumor iron nutrition and progression, beyond its function as a chemoattractant.  
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Figure 6. Proposed mechanism of CCL2-induced pathway: CCL2 (green circles), produced by breast 
tumor cells, attract circulating CCR2-positive cells, such as macrophages and lymphocytes, which are 
iron-loaded. When these stromal inflammatory cells arrive to the tumor microenvironment, FPN 1 
expression is upregulated, partially by the expression of CCL2, and iron (Fe) is supplied for 
proliferating epithelial cells. Iron supplied by macrophages and lymphocytes leads to increased 
proliferation and CCL2 secretion by tumor cells, triggering the paracrine signalling pathway, between 
tumor and immune cells. Macrophages are also accountable for the production of CCL2, resulting in 
increased leukocyte infiltration and increased iron supply for proliferating neoplastic cells. 
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Abstract 
The association of HFE major variants with breast cancer risk and behavior has been a 
matter of discussion for a long time. However, their impact on the expression of iron-related 
proteins in the breast cancer tissue has never been adressed. In the present study, hepcidin, 
ferroportin 1, transferrin receptor (TFR1), ferritin expression and tissue iron deposition were 
evaluated in a sample collection of invasive breast cancers according to the patients’ HFE 
genotype. Heterozygous patients for the p.C282Y variant presented a higher expression of 
hepcidin in lymphocytes and macrophages than wild-type or single p.H63D carrier IDC patients. An 
increased expression of TFR1 in all the cell types analyzed was also observed in p.C282Y/H63D 
compound heterozygotes, only. A differential impact of the two HFE variants was further noticed 
with the observation of a significantly higher percentage of p.C282Y heterozygous patients 
presenting tissue iron deposition in comparison to p.H63D heterozygotes. No significant 
associations were found in this study between HFE variants and the classical clinicopathological 
markers of breast cancer behavior and prognosis. Although limited by a low sampling size, our 
results suggest that HFE major variants could play a role in breast cancer progression not by 
influencing systemic iron homeostasis but rather by differentially modulating the local cellular 
expression of iron-related proteins and tissue iron deposition. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5. HFE and the Expression of Iron-Related Proteins in Breast Cancer 
 
115 
 
Introduction 
Iron is an essential trace element for the human body, as a critical component of 
several signaling, transporter and storage molecules involved in energy production and 
intermediate metabolism (Andrews, 1999; Ganz and Nemeth, 2011). However, its 
characteristic chemistry contributes to the formation of hazardous molecules, such as 
hydroxyl radicals and hydrogen peroxide, when in excess (Fenton, 1894; Halliwell and 
Gutteridge, 1992; Kalinowski and Richardson, 2005). Although most organisms have the 
proper mechanisms to regulate iron homeostasis to avoid free iron toxicity, current 
knowledge suggests that the deregulation of its regulatory mechanisms may contribute to 
a number of chronic diseases (Kell, 2009). Iron is thought to promote carcinogenesis 
through iron-induced oxidative stress, modulation of signaling networks associated with 
malignancy and by providing selective advantage to rapidly growing tumor cells (Omary et 
al., 1980; Cermak et al., 1993; Eaton and Qian, 2002; Benhar et al., 2002; Kowdley, 2004; 
Galaris et al., 2008).  
HFE is a MHC class-I like protein that acts as a gatekeeper of systemic iron 
homeostasis by controlling hepatic hepcidin levels (Schmidt et al., 2008; Vujic Spasic et 
al., 2008). Hepcidin, in turn, maintains normal plasma iron levels by regulating iron release 
from cells through the binding to its receptor, the iron exporter ferroportin 1 (Nemeth et al., 
2004; Nemeth and Ganz, 2006). A proposed molecular mechanism positions HFE and 
Transferrin Receptor 1 (TFR1) in an iron-sensing complex which is disrupted by binding of 
circulating holotransferrin with a higher affinity for TFR1 (Goswami and Andrews, 2006). 
Upon TFR1 dissociation, HFE is able to relocate to TFR2 and interact with the bone 
morphogenetic protein (Bmp) co-receptor Hemojuvelin (Goswami and Andrews, 2006; 
D'Alessio et al., 2012), involved in signal communication upon binding of the Bmp ligands, 
and whose interaction leads to the activation of hepcidin transcription (Miyazono et al., 
2005; Babitt et al., 2006; Babitt et al., 2007). However, previous evidences from others 
suggest that HFE may also act a regulator of iron uptake through its direct interaction with 
the TFR1 (Feder et al., 1996b; Lebron et al., 1998; Waheed et al., 2002). HFE gene 
variants p.C282Y and p.H63D are very common in normal European derived populations. 
The p.C282Y variant disrupts the association of HFE with β-2 microglobulin, reducing the 
cellular surface expression of HFE (Feder et al. , 1996b; Feder et al., 1997; Waheed et al., 
1997). This alteration is responsible for the large majority of hereditary hemochromatosis 
cases (Feder et al. , 1996b). The p.H63D variant is believed to lower the HFE protein 
affinity for TFR1 (Gray et al., 2009), but its association with iron overload is controversial 
(Aguilar-Martinez et al., 2001; Kelley et al., 2014; Porto et al., 2015). Although 
epidemiological studies have been inconsistent in supporting an association between HFE 
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major variants and an increased risk for breast cancer (Nelson et al., 1995; Beckman et 
al., 1999; Kallianpur et al., 2004; Abraham et al., 2005; Osborne et al., 2010), it is 
plausible to assume that, by interfering with the cellular and tissue iron homeostasis, they 
may affect the cancer cell phenotype. 
We have previously shown that the deregulation of iron-related proteins in breast 
cancer, more specifically hepcidin, ferroportin 1 (FPN1), TFR1 and ferritin (FT), is not 
restricted to epithelial cells, but also extends to cells of the tumor microenvironment 
(Marques et al., 2016). To our knowledge, no other group has attempted to verify if the 
HFE major variants had an impact on the expression of iron-related proteins in the 
neoplastic context. 
 
Materials and Methods 
Sample Characterization 
A previously characterized cohort of human breast tissue samples, archived at the 
Pathology Service at Centro Hospitalar do Porto, was used in this study. This cohort 
consisted of 120 samples, including 56 cases of invasive ductal carcinomas (IDC), 14 
cases of ductal carcinomas in situ (DCIS) and 49 samples without evidence of breast 
disease obtained from breast reduction aesthetic surgery. The study has been previously 
approved by the local Research Ethics Committees, as part of a more extended study 
(see Marques et al., 2016). Clinicopathological features, such as histological diagnosis, 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 
(HER2) statuses were retrieved from interin pathology reports. ER, PR and HER-2 status 
were assessed by immunohistochemistry. HER-2 ambiguous results were confirmed by 
FISH. 
Tissue Microarray Construction and Immunohistochemistry 
Tissue microarray construction and immunohistochemistry for hepcidin, FPN1, 
TFR1 and FT for this cohort have been extensively described before (Marques et al., 
2016). Immunostaining for hepcidin, FPN1, TFR1 and FT was evaluated in epithelial cells, 
lymphocytes and macrophages using the same semi-quantitative evaluation method as 
before (Marques et al., 2016). Cores from the same donor tissue were grouped and their 
mean score for each variable calculated. 
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DAB-enhanced Perls’ Prussian Blue Staining 
To evaluate the presence of iron deposition in breast samples, DAB-enhanced 
Perls’ Prussian Blue was performed, adapted to the Van Duijn protocol (Van Duijn et al., 
2013).  
DNA Extraction and HFE Genotyping 
Genomic DNA was extracted from FFPE breast sections according to the 
Ultraprep Tissue DNA kit (AHN Biotechnologie, Nordhausen, Germany) recommended 
procedures. PCR was carried out in 15.5μL reaction volumes, containing 2μL of the 
genomic DNA template, 7.5μL of MasterMix DNA polymerase, 1μL of Q-solution (Qiagen 
Multiplex PCR kit, Valencia, CA, USA) and 1μL of each of sense and antisense primers. 
For the detection of the p.C282Y variant the following primers were used: 5'-
CAAGTGCCTCCTTTGGTGAAGGTGACACAT-3' as the forward primer and 5’-
CTCAGGCACTCCTCTCAACC-3’ as the reverse primer (Metabion, Steinkirchen, 
Germany). Following the verification of the 343 bp fragment amplification RsaI was used 
for restriction. For the HFE p.H63D variant, the following forward and reverse primers’ 
sequences were used:  5’-ACA TGG TTA AGG CCT GTT GC-3’ and 5’-GCC ACA TCT 
GGC TTA AAA TT-3’ (Metabion, Steinkirchen, Germany). In turn, these primers amplify a 
fragment with 294 bp that was then restricted by MboI. Primers for detection of variants in 
the HFE gene were chosen according to the work of Feder et al. (Feder et al., 1996a). 
The PCR program included a step of 95ºC, for 15 minutes followed by 36 cycles of 
denaturation at 94ºC for 30 seconds, annealing at 58ºC for 90 seconds and extension at 
72ºC for 90 seconds. Reaction was extended in the final for 10 minutes at 72ºC.  
Statistical Analysis 
Data were analyzed with IBM SPSS Statistics Version 18.0 (SPSS Inc., IBM, 
Chicago, IL, USA). Sample distributions were compared by the Kruskal-Wallis test 
followed by post-hoc testing whenever the omnibus testing was significant. Pearson’s Chi-
Square was used to evaluate the differences between categorical variables. In figures, 
experimental errors are shown as 95% Confidence Intervals (CI). Statistical significance 
was accepted at p< 0.05.  
Once no p.C282Y heterozygotes were found within the aesthetic breast reduction 
population, comparisons for this variant were restricted to breast cancer cases. 
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Results 
Expression of Iron-Related Proteins 
No significant differences were found in the expression of the analyzed iron-related 
proteins between wild-type individuals and p.H63D carriers included in the aesthetic 
breast reduction population for all cell types. Similarly, no significant differences were 
found for the expression of these proteins in DCIS among all the genotypes considered. In 
invasive breast carcinoma (IDC) cases, however, the expression of hepcidin in 
lymphocytes and macrophages was significantly higher in patients carrying the p.C282Y 
variant (p< 0.05; Figure 1A) relative to both wild type and p.H63D carriers. No further 
differences were found regarding the expression of FPN1, TFR1 and FT in IDC cases 
(Figure 1B-D).  
 
Figure 1. Iron-related proteins in invasive breast carcinomas according to HFE genotype. Median 
hepcidin (A), FPN1 (B), TFR1 (C) and FT (D) expression, in epithelial cells, lymphocytes and 
macrophages, in relation to the presence or absence (WT) of the p.C282Y and p.H63D variants. Scores 
ranged from 0 to 15 and errors bars present 95% CI. Abbreviations: WT, Wild-Type; FPN1, ferroportin 
1; TFR1, transferrin receptor 1; FT, ferritin; EC, Epithelial Cells; Ly, Lymphocytes; M0, Macrophages 
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To further clarify the relative impact of the two variants in the results observed, we 
focused the analysis on a sub-sample of p.C282Y/p.H63D compound heterozygotes. 
Remarkably, from the 9 p.C282Y carriers with IDC, 5 were compound heterozygotes. 
Although these did not differ in general from the other p.C282Y/WT IDC patients in terms 
of the expression of the iron-related proteins, they differed significantly from non-p.C282Y 
carriers not only by a higher expression of hepcidin in lymphocytes and macrophages (as 
described in the whole p.C282Y carrier population) but they showed, in addition, an 
increased expression of TFR1 in all the cell types analyzed (Table 1). 
 
Table 1. Expression of iron-related proteins in HFE p.C282Y/p.H63D compound 
heterozygous IDC patients is increased in comparison with patients without the p.C282Y 
variant. 
*
 represents significant differences (p< 0.05) for comparison with the non-p.C282Y 
carriers group. Abbreviations: IDC, invasive ductal carcinoma; SEM, Standard Error of the 
Mean; EC, Epithelial Cells; Ly, Lymphocytes; M0, Macrophages; NS, Non-Significant 
Iron-Related 
Proteins (Mean ± 
SEM) 
non-p.C282Y 
carriers (n= 47) 
p.C282Y/p.H63D 
heterozygous 
compounds (n= 5) 
p.C282/WT 
heterozygous (n= 4) 
Hepcidin       
EC 1.06 ± 0.28 3.4 ± 2.93 6.38 ± 3.33 
Ly 0.80 ± 0.16 2.17 ± 0.69* 2.00 ± 0.58 
M0 1.56 ± 0.32 3.60 ± 0.98* 3.83 ± 1.30 
FPN1       
EC 5.54 ± 0.39 6.11 ± 1.02 6.13 ± 1.71 
Ly 6.67 ± 0.54 8.43 ± 1.06 4.28 ± 1.88 
M0 6.17 ± 0.43 7.90 ± 0.75 4.61 ± 1.69 
TFR1       
EC 7.25 ± 0.51 11.00 ± 1.72* 7.65 ± 1.98 
Ly 3.70 ± 0.32 5.80 ± 0.97* 4.33 ± 0.88 
M0 6.14 ± 0.38 9.68 ± 1.42* 7.50 ± 2.25 
FT       
EC 10.09 ± 0.35 8.92 ± 0.74 9.06 ± 0.60 
Ly 8.89 ± 0.24 8.50 ± 1.07 6.88 ± 0.59* 
M0 14.83 ± 0.12 15.00 ± 0.00 14.17 ± 0.83 
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Tissue Iron Deposition 
Regarding tissue iron deposition in invasive breast carcinomas, a significantly 
lower percentage of p.H63D carrier IDC patients presented iron deposits in epithelial and 
stromal inflammatory cells, compared with the two other genotypes considered (p< 0.05; 
Figure 2). Differences between wild-type and p.C282Y heterozygotes were not statistically 
significant. From the p.C282Y carrier IDC patients displaying iron deposits in epithelial 
cells, all of them were compound heterozygotes and from the ones with iron deposition in 
stromal inflammatory cells, 4 out of 5 were compound heterozygotes. 
 
Figure 2. Iron deposition in invasive breast carcinomas according to the HFE genotype. Percentage of 
invasive breast cancer cases presenting iron deposition in epithelial (black) and stromal inflammatory 
(grey) cells, in relation to the HFE genotype. Abbreviations: WT, Wild-Type 
 
Clinicopathological Data 
Hormone receptor and HER2 status, lymph node involvement and tumor size were 
available from the interin records and were also analyzed regarding the HFE genotype. 
None of the different genotypes were associated with any of the considered variables of 
poor outcome (Table 2). 
  
1
2
1
 
Table 2. Clinicopathological features of breast cancer patients according to their HFE genotype. Abbreviations: DCIS, ductal carcinoma in situ; 
IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor, HER2, Human Epidermal growth factor Receptor 2; LN, lymph-
node; IQR, interquartile range; NS, non-significant 
 
DCIS   IDC 
Factors 
WT p.H63D carriers p.C282Y carriers 
p  
WT p.H63D carriers 
p.C282Y 
carriers p 
n (%) n (%) n (%) 
 
n (%) n (%) n (%) 
ER status, n (%)a       
NS 
 
      
NS negative 
2 
(28.6%) 
1 (25.0%) 2 (66.7%) 
 
7 (22.6%) 3 (16.7%) 3 (37.5%) 
positive 
5 
(71.4%) 
3 (75.0%) 1 (33.3%) 
 
24 (77.4%) 15 (83.3%) 5 (62.5%) 
PR status, n (%)a   
  
NS 
 
  
  
NS negative 
3 
(42.9%) 
2 (50.0%) 2 (66.7%) 
 
8 (25.8%) 5 (27.8%) 4 (50.0%) 
positive 
4 
(57.1%) 
2 (50.0%) 1 (33.3%) 
 
23 (74.2%) 13 (72.2%) 4 (50.0%) 
HER2 status, n (%)a       
NS 
 
      
NS negative 
4 
(57.1%) 
1 (33.3%) 2 (66.7%) 
 
24 (77.7%) 13 (76.5%) 4 (50.00%) 
positive 
3 
(42.9%) 
2 (66.7%) 1 (33.3%) 
 
7 (22.6%) 4 (23.5%) 4 (50.00%) 
LN metastasis, n 
(%)a 
      
  
 
  
  
NS 
non-metastized       
 
17 (56.7%) 4 (22.2%) 4 (50.0%) 
metastized       
 
13 (43.3%) 14 (77.8%) 4 (50.0%) 
Median tumor size 
(IQR)b 
        
 
1.00 (1.00 - 
2.00) 
1.00 (1.00 - 
2.00) 
1.00 (1.00 - 
1.50) 
NS 
a Pearson Chi-Square 
        b Kruskal Wallis Test 
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Discussion 
The fact that HFE variants are much more prevalent than the iron overload 
disorder hereditary hemochromatosis (Waalen et al., 2005) contributed to an increasing 
interest in the HFE gene as a risk factor or disease modifier in various chronic diseases, 
such as cancer. However, genetic association studies have not been successful in 
demonstrating a clear relationship between HFE major variants and increased breast 
cancer risk (Nelson et al., 1995; Beckman et al., 1999; Abraham et al., 2005; Osborne et 
al., 2010). 
In our study, we describe a higher expression of hepcidin in lymphocytes and 
macrophages of IDC patients with the p.C282Y variant (Figure 1A, Table 1). Although 
other studies suggest that, in general, hepcidin expression does not differ significantly 
from that of healthy subjects (Roe et al., 2007), we cannot ignore the local regulation and 
the possibility that an association between HFE variants and other proteins, such as p16, 
may be cell-specific or even restricted to neoplastic context (Lee et al., 2011). 
Furthermore, p.C282Y/p.H63D compound heterozygous IDC patients display a more 
drastic phenotype by enhanced expression of TFR1 in all the cell types analyzed. A study 
by Piperno and colleagues has demonstrated that, at the time of diagnosis, while p.C282Y 
homozygous HFE patients presented comparable hepcidin levels to controls, compound 
heterozygotes displayed increased values (Piperno et al., 2007). Furthermore, the p.H63D 
variant, in association with the p.C282Y has been associated with increased hepatic iron 
concentrations (Bacon et al., 1999; Brissot et al., 1999). Particularly, in a study with 
healthy women, increased serum iron levels and transferrin saturation were observed in 
compound heterozygotes, but not in p.C282Y/WT, when compared with women with none 
of the variants (Rossi et al., 2000). The increased iron deposition in epithelial and stromal 
inflammatory cells of IDC patients with the p.C282Y variant may, thus, be a consequence 
of not only increased iron retention due to the local hepcidin effect but also due to 
increased TFR1 expression as a result of neoplastic epithelial cells’ ‘iron-deficient’ 
phenotype (Pinnix et al., 2010; Wang et al., 2014; Zhang et al., 2014) and stromal 
inflammatory cells’ activation (Manger et al., 1986; Paulnock and Lambert, 1990). 
The fact that only differences in IDC patients were found may partially explain the 
inconsistent results trying to relate the p.C282Y variant and breast cancer risk.  Although 
others have observed an increased prevalence of the p.C282Y variant with a higher 
number of lymph-nodes affected (Abraham et al. , 2005) we have not found any 
association between classic clinicopathological markers in breast cancer and any of the 
HFE genotypes considered. Although a slightly higher prevalence of the p.C282Y variant 
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was observed in patients with markers of poor outcome (ER-, PR-, HER2+), the 
insufficient sampling size does not allow us to draw further conclusions.  
In conclusion, in spite of the limitation of this study due to low population numbers, 
the results give further support to the concept of an alternative role for HFE in chronic 
diseases through modulation of local iron homeostasis, and highlights the need to a more 
insightful knowledge of the role of HFE in cancer. 
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Abstract 
Breast cancer is characterized by a deregulation in cellular iron homeostasis, as 
reflected by the altered expression of its regulatory proteins. Malignant epithelial cells 
present higher iron requirements, behaving as ‘iron-deficient’, while stromal inflammatory 
cells may act as ‘iron-donors’.  The expression of iron-related proteins in the mammary 
gland of cats and dogs has never been assessed before. We evaluated the expression of 
Hepcidin, Ferroportin 1 (FPN1), Transferrin Receptor 1 (TFR1) and Ferritin (FT) in 
epithelial cells, lymphocytes and macrophages of cats and dogs’ benign and malignant 
mammary gland lesions. Iron deposition was detected with Perls’ Prussian Blue staining. 
Unlike human breast cancer, no major differences were found in the expression of the 
iron-related proteins between benign and malignant mammary gland lesions from cats 
and dogs. However, cats and dogs show accumulation of iron in benign lesions, 
demonstrated by the high percentage of samples presenting hemosiderin deposition, thus 
providing an explanation for the absence of higher iron requirements by tumor cells.  
Although a role for iron-induced chronic oxidative stress cannot be excluded, physiological 
differences in relation to human breast cancer demand a more profound knowledge of 
local iron homeostasis in cats and dogs. 
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Introduction 
Breast cancer is the most frequent neoplasia in women worldwide. Although recent 
advances in early diagnostic and therapeutic regimens have led to lower mortality rates, 
breast cancer is still by far the most frequent cancer in women and the second most 
frequent cause of cancer death in developed countries (Ferlay et al., 2013). Likewise, 
mammary tumors are the most common form of cancer in female intact dogs and the third 
most frequent in intact cats (Moulton, 1990; Misdorp et al., 1999; Misdorp, 2002; 
Goldschmidt et al., 2011). Despite livelong discussion about the role of animal models in 
human research, there is evidence for the similarities between human breast cancer and 
both canine and feline mammary gland tumors. These include the spontaneous 
occurrence of tumors and relative early age of onset, hormonal influence, histological 
features, biological behavior and therapy response (Pang and Argyle, 2009; Queiroga et 
al., 2011; Rivera and Von Euler, 2011; Matos et al., 2012). Despite this, and aside from 
BRCA1 and 2 (Rivera et al., 2009), TP53 (Borge et al., 2011) in dogs and HER-2/neu in 
cats (Millanta et al., 2005; Ordas et al., 2007), transversal molecular targets associated 
with carcinogenesis remain largely unknown or present inconsistent results. Thus, it 
remains imperative to pursue further insights in comparative oncology, not only for human 
research extrapolation but also for the pets’ benefit. 
One such example is iron’s role in breast carcinogenesis. Due to its ability to 
accept and donate electrons, iron is an essential element and a critical component of 
sensor, transporter and storing molecules and enzymes involved in energy production and 
intermediate metabolism (Andrews, 1999; Cairo et al., 2006; Ganz and Nemeth, 2011). At 
systemic level, hepcidin is responsible for regulating iron absorption, and ultimately iron 
homeostasis, through its ability to down-modulate the cellular expression of ferroportin 1, 
the only known iron exporter (Nemeth et al., 2004; Knutson et al., 2005). Cellular iron 
uptake is regulated by the presence of the transferrin receptor 1 (TFR1), through binding 
to transferrin and internalization of the iron-loaded complex (Klausner et al., 1983a; 
Klausner et al., 1983b). To avoid free iron associated toxicity, iron not being used for 
cellular purposes is stored inside ferritin (FT), an ubiquitous heteropolymer composed of 
24 heavy and light subunits (Harrison and Arosio, 1996; Arosio et al., 2009). 
Comprehensive data supports a role for iron-mediated carcinogenesis (Huang, 2003). 
Paths proposed include DNA, protein and organelle damage through iron-induced 
oxidative stress (Nelson, 1992; Toyokuni, 1996; Eaton and Qian, 2002), further activation 
of signaling pathways associated with oncogenesis (Benhar et al., 2002; Kowdley, 2004; 
Galaris et al., 2008) and selective advantage for malignant cell clonal expansion (Omary 
et al., 1980; Cermak et al., 1993). Particularly, studies in animal models have consistently 
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demonstrated that subcutaneously injected iron and the administration of iron-rich diets 
promotes mammary gland tumor development and progression (Thompson et al., 1991; 
Singh et al., 1994; Hrabinski et al., 1995; Diwan et al., 1997).  
Although the malignant state in human breast cancer cells has been characterized 
by a deregulation in cellular iron homeostasis, and consequently in the expression of iron-
regulatory proteins, this issue has never been addressed in canine and feline mammary 
tumors. In the present study we analyzed the expression of iron-regulatory proteins 
hepcidin, ferroportin 1, transferrin receptor 1 and ferritin in both canine and feline 
mammary epithelial cells, lymphocytes and macrophages from benign and malignant 
lesions. This approach allowed us to conclude that the expression of these iron-related 
proteins does not differ from benign to malignant lesions from cats and dogs, because 
there is already an evident strong iron accumulation in normal mammary gland tissues. 
 
Materials and Methods 
Sample characterization 
Paraffin-embedded blocks from 68 cats and 62 dogs archived in the Veterinary 
Pathology Laboratory (ICBAS) and the Histology and Anatomical Pathology Laboratory 
(UTAD) from 2001 to 2011 were included in this study. From the sampled animals, 59 cats 
presented carcinomas and 9 had benign alterations (including fibroadenomatous 
alterations and hyperplasias). Regarding the dogs, 36 presented carcinomas and 26 
benign lesions (including hyperplasias, adenomas and benign mixed mammary tumors). 
All mammary lesions were histologically classified according to the criteria defined by the 
World Health Organization (WHO) for the classification of dog and cat mammary tumors 
by three veterinary pathologists (AC, FS and AG). Histological grading of tissue samples 
was performed through a modified Elston and Ellis method (Elston and Ellis, 1991), by 
assessment of the degree of tubular formation, nuclear polymorphism and mitotic activity, 
in 5 high power fields, as previously described for cats (Seixas et al., 2011) and dogs 
(Clemente et al., 2010).  
Tissue Microarray construction  
The correspondent formalin-fixed paraffin-embedded (FFPE) tissue blocks and 
their corresponding hematoxylin and eosin (H&E)-stained slides were retrieved from the 
archives and carefully analyzed by a pathologist (CL, FS and AG) as to select target 
areas. Whenever possible, non-malignant lesions were selected from carcinoma cases, to 
ensure tissue representativity. Sections of human liver were obtained from the archive of 
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the Pathology Department of Santo António Hospital, Porto Hospital Centre, and were 
included in each tissue microarray block, as positive controls.  
Immunohistochemistry 
Immunohistochemistry was performed on 2 µm tissue microarray paraffin-
embedded sections with the following antibodies; hepcidin (dilution 1/500, Abcam, 
Cambridge, UK), ferroportin 1 (FPN1 - 1/750, Novus Biologicals Europe, Cambridge, UK), 
CD71 (TFR1 [clone 10F11] - 1/80, Novocastra, Newcastle, UK) and ferritin (FT - 1/1000, 
Sigma-Aldrich, MO, USA). Briefly, sections were deparaffinized in xylene and rehydrated 
in decreasing concentration of ethanol and washed in water, for 5 minutes each. Heat-
mediated antigen target retrieval was done with DAKOTarget Retrieval Solution (Agilent 
Technologies, Denmark) in a water-bath, at 99.5ºC, during 25 minutes. 
Immunohistochemistry was then performed according to Novolink Polymer Detection kit 
procedures (Leica, Biosystems, Cambridge, UK). Enzyme reactivity was visualized using 
3,3′-Diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich, MO, USA) and slides were 
counterstained with Mayers hemalum solution (Merck Millipore, Darmstadt, DE), 
dehydrated and mounted with Entellan (Merck Millipore, Darmstadt, DE). The reaction 
product was analyzed in a Leica DM LB microscope. Antibody optimum dilutions were 
determined in each species’ tissue-positive controls (hepcidin – liver, FPN1 – duodenum, 
TFR1 – tonsil, FT – spleen). Negative controls were performed by replacing the primary 
antibody with an antibody of the same immunoglobulin isotype, as well as a section of 
liver tissue from a HAMP KO mouse. 
Staining Criteria 
Immunostaining for hepcidin, FPN1, TFR1 and FT was evaluated in luminal 
epithelial cells, lymphocytes and macrophages. A semi-quantitative evaluation method 
was applied: the percentage of positive cells (0 points: 0%; 1 point: 1-10%, 2 points: 11-
20%, 3 points: 21-35%, 4 points: 36-50% and 5 points:  >50%) and the staining intensity 
(0 points: no staining, 1 point: weak staining, 2 points: moderate staining and 3 points: 
strong staining) were considered and multiplied. Cores from the same donor tissue were 
grouped and their mean score calculated. 
Perls’ Prussian Blue staining 
Hemosiderin deposits were detected by the routine technique of Perls’ Prussian 
Blue staining.  After deparaffinization and rehydration in the ethanol series, 2 µm tissue 
microarray sections were immersed in a mixture of equal volumes of potassium 
ferrocyanide solution and hydrochloric acid solution (2%) at 60ºC, during 20 minutes. 
Counterstaining was achieved with nuclear fast red (Merck Millipore, Darmstadt, 
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Germany). The absence or presence of hemosiderin deposits was evaluated in epithelial 
and stromal inflammatory cells. 
Electron Microscopy 
Mammary gland samples were obtained during necropsy procedures from one dog 
and one cat who died from non-infectious and non-neoplastic causes. Absence of 
mammary gland disease was confirmed by routine H&E staining. Mammary gland and 
liver samples were fixed for about 2 h at 4ºC in 2.5% glutaraldehyde and 4% 
formaldehyde (obtained from hydrolysis of para-formaldehyde), diluted with cacodylate 
buffer (0.1 M), pH 7.3. After being washed in the buffer, half the samples were processed 
with Perls’ Prussian Blue en bloc, as described previously, but incubated during 40 min. In 
the other half of the samples this step was omitted. All samples were then postfixed with 
2% osmium tetroxide (OsO4) buffered with cacodylate, dehydrated in increasing 
concentrations of ethanol and embedded in Epon. In order to identify the areas of 
hemosiderin deposition, semithin sections from the samples previously subjected to Perls’ 
Prussian Blue reaction en bloc, were treated with an ethanol saturated solution of sodium 
hydroxide to remove the epoxy resin and counterstained with nuclear fast red (Merck 
Millipore, Darmstadt, Germany). Ultrathin sections, with and without double staining with 
aqueous uranyl acetate and lead citrate were obtained in JEOL 100CXII transmission 
electron microscope operated at 60 kV. 
Statistical Analysis 
Sample distributions were compared using the Mann-Whitney test. Pearson’s Chi-
Square was used to evaluate the differences between categorical variables. The 
Spearman’s rank correlation coefficient was used to evaluate the relationship between 
variables. Data were analyzed in IBM SPSS Statistics 20.0 software and statistical 
significance was accepted at p< 0.05. 
 
Results 
Iron-related proteins immunoexpression in tissue sections 
The immunoexpression of hepcidin, FPN1, TFR1 and FT was assessed in both 
benign and malignant mammary gland tissue from cats and dogs and the respective 
results are shown in Table 1. 
  
1
3
5
 
Table 1. Immunoexpression of iron-related proteins in mammary gland tissue 
    
Hepcidin 
Sig.
2
 
FPN1
3
 
Sig. 
TFR1
4
 
Sig. 
FT
5
 
Sig. 
(Mean ± SEM
1
) (Mean ± SEM) (Mean ± SEM) (Mean ± SEM) 
C
A
T
 
EC
6
 n= 66 
NS
9
 
n= 60 
NS 
n= 66 
NS 
n= 65 
p= 0.009 Benign Lesion 2.87 (± 0.72) 9.06 (± 0.91) 1.50 (± 0.53) 11.43 (± 0.75) 
Malign Lesion 1.83 (± 0.34) 9.77 (± 0.47) 1.40 (± 0.21) 9.14 (± 0.36) 
Ly
7
 n= 32 
NS 
n= 35 
NS 
n= 54 
NS 
n= 37 
NS Benign Lesion 4.22 (± 2.12) 2.50 (± 0.50) 1.28 (±  0.67) 12.50 (± 0.00) 
Malign Lesion 2.50 (± 0.56) 3.28 (± 0.36) 0.91 (± 0.23) 8.79 (± 0.61) 
M0
8
 n= 35 
NS 
n= 37 
NS 
n= 52 
p= 0.005 
n= 56 
NS Benign Lesion 10.33 (± 1.67) 4.50 (± 0.50) 7.67 (± 1.56) 14.69 (± 0.31) 
Malign Lesion 6.88 (± 0.61) 7.41 (± 0.52) 3.29 (± 0.53) 14.90 (± 0.07) 
                    
D
O
G
 
EC n= 60 
NS 
n= 52 
NS 
n= 56 
NS 
n= 57 
NS Benign Lesion 1.69 (± 0.27) 10.11 (± 0.74) 2.88 (± 0.51) 10.07 (± 0.53) 
Malign Lesion 1.45 (± 0.29) 10.66(± 0.60) 2.40 (± 0.29) 10.10 (± 0.37) 
Ly n= 30 
NS 
n= 28 
NS 
n= 47 
NS 
n= 28 
NS Benign Lesion 1.79 (± 0.41) 5.78 (± 1.38) 0.75 (± 1.19) 8.60 (± 1.31) 
Malign Lesion 2.89 (± 0.61) 4.80 (±  0.75) 1.15 (± 0.26) 9.13 (± 0.69) 
M0 n= 26 
NS 
n= 33 
NS 
n= 50 
NS 
n= 52 
NS Benign Lesion 12.04 (± 0.82) 8.72 (± 1.15) 7.57 (± 0.61) 14.77 (± 0.22) 
Malign Lesion 8.93 (± 1.20) 7.72 (± 0.50) 8.02 (± 0.45) 14.92 (± 0.08) 
1
SEM, Standard Error of the Mean; 
2
Sig., Significance; 
3
FPN1, Ferroportin 1; 
4
TFR1, Transferrin Receptor 1; 
5
FT, Ferritin; 
6
EC, Epithelial Cells; 
7
Ly, Lymphocytes; 
8
M0, 
Macrophages; 
9
NS, Non-Significant 
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Results for individual types of lesions are shown in Supplementary Tables 1 (cat) 
and 2 (dog). Representative images of the staining patterns are illustrated in Fig. 1. 
 
Figure 1. Hepcidin, FPN1, TFR1 and FT expression pattern in the mammary gland tissue of cats and 
dogs. Representative images of the Hepcidin, FPN1 (Ferroportin 1), TFR1 (Transferrin Receptor 1) and 
FT (Ferritin) immunostaining in benign and malignant breast lesions. Tissue microarrays containing 
several samples of cats’ and dogs’ mammary tissue were constructed, sectioned and subjected to 
immunohistochemistry, as described in materials and methods. Below each 200× original 
Chapter 6. Expression of Iron-Related Proteins in Feline and Canine Mammary Gland Reveals Unexpected 
Accumulation of Iron 
 
 
137 
 
magnification image is a 400×-magnification paired image (Scale bar in 200× magnification images - 50 
µm; Scale bar in 400× magnification images -25 µm). 
Hepcidin expression was observed in the cytoplasm of all the cell types evaluated. 
No significant differences were observed for the hepcidin expression in epithelial cells, 
lymphocytes or macrophages between benign and malignant mammary gland tissue of 
cats and dogs. 
Similarly, ferroportin 1 expression was also mainly observed in the cytoplasm of all 
the cell types assessed, although in some samples, a clear membranous staining in 
epithelial cells was also noticed. As for hepcidin, no significant differences in FPN1 were 
detected between benign and malignant mammary gland tissues for the cell types 
evaluated.  
TFR1 expression was predominantly detected in the cytoplasm of every cell type 
evaluated. However, in some cases membranous staining was also detected in epithelial 
cells. As for the previous iron-related proteins described no significant differences were 
observed between benign and malignant mammary gland tissue samples, except for 
TFR1 expression in macrophages from cats’ mammary gland tissue. In this species, 
macrophages from benign tissues presented a significantly higher expression of TFR1 
than in malignant tissues (p= 0.005). 
Ferritin immunoexpression was mainly observed in the cytoplasm of the cell types 
assessed. As for the other iron-related proteins, regarding dogs’ tissue, no significant 
differences were found between benign and malignant lesions. However, in cats’ 
mammary gland tissue, a significant higher expression of ferritin in epithelial cells was 
found in benign lesions, when comparing with malignant ones (p= 0.009). Nuclear FT 
staining in epithelial cells from some samples was noted. 
Clinicopathological data 
The expression of these iron-related proteins was correlated with grade based on 
modified schemes of Elston and Ellis classification, currently the most powerful prognostic 
factor recognized for cats and dogs mammary tumors (Clemente et al., 2010; Seixas et 
al., 2011). Results are shown in Table 2. FT expression in epithelial cells was negatively 
associated with increasing tumor grade in cats (p= 0.017). All other comparisons, either 
for cat or dog, were not statistically significant. 
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Table 2. Correlation table between grade and the 
expression of iron-related proteins 
   
Grade 
      n r Sig.
1
 
C
A
T
 
H
e
p
c
id
in
 
EC
2
 62 0.058 0.671 
Ly
3
 31 -0.032 0.869 
M0
4
 34 0.248 0.158 
F
P
N
1
5
 EC 58 0.087 0.527 
Ly 33 -0.048 0.793 
M0 33 -0.190 0.290 
T
F
R
1
6
 EC 63 -0.056 0.672 
Ly 53 -0.226 0.111 
M0 51 -0.151 0.307 
F
T
7
 
EC 61 -0.317 0.017 
Ly 36 -0.220 0.198 
M0 53 -0.080 0.579 
            
D
O
G
 
H
A
M
P
 EC 60 0.146 0.267 
Ly 30 -0.001 0.997 
M0 36 0.021 0.920 
F
P
N
1
 EC 52 0.174 0.216 
Ly 28 0.027 0.891 
M0 33 0.229 0.201 
T
F
R
1
 EC 56 -0.143 0.293 
Ly 47 0.063 0.675 
M0 49 0.059 0.687 
F
T
 
EC 56 0.088 0.518 
Ly 28 -0.066 0.737 
M0 52 -0.047 0.740 
1
Sig., Significance; 
2
EC, Epithelial Cells, 
3
Ly, Lymphocytes; 
4
M0, 
Macrophages; 
5
FPN1, Ferroportin 1;
 6
TFR1, Transferrin Receptor 1;
 7
Ferritin, 
Ferritin 
 
Iron deposition by Perls’ Prussian Blue Staining 
Our group has previously described that the human breast malignancy is 
characterized by a deregulation on the expression of iron-related proteins not only in 
epithelial cells, but also in lymphocytes and macrophages (Marques et al., 2014b). Given 
the fact that we have not found major differences in the expression of these proteins 
between benign and malignant mammary lesions of the cat and dog, we assessed iron 
deposition in the epithelial and stromal inflammatory cell compartments, to verify if this 
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could account for the absence of differences in the expression of proteins that regulate 
cellular iron homeostasis. In fact no differences were found, either for the epithelial or 
stromal inflammatory cells compartment, for the percentage of cases presenting iron 
deposition between benign and malignant tissues from cats and dogs (p> 0.05) (Fig. 2).  
 
Figure 2. Iron accumulation in the mammary tissue of cats and dogs. The percentage of cases 
presenting hemosiderin deposition, as assessed by Perls’ Prussian Blue staining, in epithelial and 
stromal inflammatory cells from benign and malignant mammary lesions from cats and dogs is 
shown. 
 
Notably, Perls’ Prussian Blue histochemical staining of the mammary gland 
samples from one necropsied dog and cat, without evidence of neoplastic disease, also 
revealed hemosiderin accumulation in epithelial cells and macrophages (Fig. 3A). 
Subsequent ultrastructural analysis allowed the identification of highly electron-dense 
Prussian Blue deposits within dense bodies, visible in both stained and unstained ultrathin 
sections (Fig. 3B,C). These iron-containing dense bodies, known as siderosomes, had an 
average diameter of about 0.5 µm and were located close to the nucleus of epithelial cells. 
In control samples without Perls’ reaction, the highly electron-dense deposits were absent 
(Fig. 3D).  
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Figure 3. Light (A) and electron microscopy (B-C) detection of iron by Perls’ Prussian Blue staining in 
a normal canine mammary gland. (A) Positive reaction for hemosiderin in macrophages (arrows) and 
in small granules (arrowheads) located close to the nucleus (nu) in epithelial cells of mammary ducts 
(asterisks) (Scale bar - 50 µm; Scale bar in inset - 10 µm); (B) Unstained ultrathin section showing 
highly electron-dense Prussian blue deposits (arrowheads) within siderosomes close to the nucleus 
(nu) in an epithelial cell (Scale bar - 0.5 µm); (C) Stained ultrathin section also revealing iron deposits 
(arrowheads) within siderosome (Scale bar - 0.5 µm); (D) Siderosome (asterisk) in a stained ultrathin 
section of a control sample without Perls' reaction (Scale bar - 0.2 µm) 
 
Discussion 
As a critical component of several sensor, transporter and storing molecules and 
enzymes responsible for energy production and intermediate metabolism (Ganz and 
Nemeth, 2011), iron is an essential transition metal for cell survival, growth and 
differentiation (Andrews, 2008). However, this constant requirement for iron becomes 
challenging in a way that the organism must acquire enough iron for its needs, while 
avoiding free iron toxicity (Andrews and Schmidt, 2007) and consequent increase in 
Chapter 6. Expression of Iron-Related Proteins in Feline and Canine Mammary Gland Reveals Unexpected 
Accumulation of Iron 
 
 
141 
 
oxidative stress and cell damage (Toyokuni, 1996; Mccord, 2004). Besides ‘iron-overload’ 
classical diseases such as hereditary hemochromatosis and thalassemias a growing body 
of evidence links imbalances of iron homeostasis with several chronic and 
neurodegenerative diseases (Kell, 2009).  
Current knowledge supports the hypothesis that iron may affect the development, 
behavior and progression of cancer (Kwok and Richardson, 2002; Huang, 2008). 
Particularly in human breast cancer, several studies highlight that the malignant state is 
characterized by a deregulation of iron homeostasis, as shown by an altered expression 
of its regulatory proteins (Marques et al., 2014a). Human breast cancer epithelial cells are 
characterized by an ‘iron-deficient’ phenotype as demonstrated by the massive 
upregulation of the iron importer TFR1 (Faulk et al., 1980; Yang et al., 2001; Habashy et 
al., 2010; Singh et al., 2011) and lower levels of the iron storage protein ferritin (Rossiello 
et al., 1984; Alkhateeb et al., 2013) and ferroportin 1, the iron exporter, (Pinnix et al., 
2010; Zhang et al., 2014) than with their normal counterparts. Overall, this appears to 
contribute to an increase of the metabolically available iron (labile iron pool), and 
proliferative and malignancy potential (Pinnix et al. , 2010; Zhang et al. , 2014). In this 
respect, besides the significantly lower ferritin expression in cats’ malignant tumors, we 
were not able to replicate the results found for human breast cancer epithelial cells in cats’ 
and dogs’ mammary tumors. Additionally, our group has recently demonstrated that 
human breast tumor infiltrating lymphocytes and macrophages present an ‘iron-donor’ 
phenotype, characterized by a higher expression of both FPN1 and FT and a concomitant 
activation profile, as reflected by the also higher expression of hepcidin and TFR1 
(Marques et al. , 2014b). Assessment of these iron-related proteins in tumor-infiltrating 
lymphocytes and macrophages from cats and dogs’ mammary gland tissue also did not 
reflect human findings, suggesting that these cells do not present a particular ‘iron-donor’ 
phenotype in malignant samples. 
Given the recognition that tumor cells are highly iron-dependent due to its 
proliferative activity (Sutherland et al., 1981; Trowbridge and Domingo, 1981; Taetle and 
Honeysett, 1987; Trinder et al., 1996;) at least a higher expression of TFR1 in tumor 
epithelial cells would be expected. As this was not observed, a plausible explanation could 
be that these cells were not ‘iron-deficient’. With this in mind, we evaluated hemosiderin 
deposition in epithelial and stromal inflammatory cells in the same samples. The finding 
that 44% of all cat and 73% of all dog samples presented iron deposition in mammary 
gland tissue epithelial cells was surprising, contrasting with the much lower percentage 
that we previously found in human breast cancer specimens (~14%). But in contrast to the 
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human cohort, where a significantly higher percentage of breast cancer cases presented 
iron accumulation in epithelial and stromal inflammatory cells, when compared with 
reduction aesthetic surgery samples (Marques et al. , 2014b), in the present models, we 
found no evidence to support any relation between iron-laden macrophages and the dog 
and cat neoplasms. This suggests that cats and dogs’ tumors do not need to alter the  
expression of iron-related proteins as an approach to acquire or maintain more iron for 
proliferating tumor cells, given that epithelial cells from normal or benign tissues already 
accumulate a sufficiently large amount of iron in comparison to what is seen in human 
breast tissues.  
Breast epithelial cells that line the smaller ducts and alveoli of the mammary gland 
are responsible for the elaboration and secretion of a large part of milk components 
(Seelig and Beer, 1978; Ballard and Morrow, 2013). Cats and dogs secrete milk in which 
the concentration of iron is several times higher than in human milk (Keen et al., 1982). 
This suggests a higher retention of iron in cats and dogs’ mammary tissue and hence 
providing a plausible explanation for the lack of additional iron requirements for tumor 
cells. Analysis of normal mammary gland tissue stained with Perls’ Prussian Blue 
reinforced our light microscopy results by revealing the presence of iron-containing 
bodies, known as siderosomes, in the cytoplasm. Although we cannot clearly identify the 
origin of these siderosomes, we hypothesize that these are of lysosomal nature given that 
other authors have previously demonstrated that hemosiderin accumulates in lysosomes 
in macrophages and epithelial cells, such as hepatocytes and kidney epithelial cells 
(Dullmann et al., 1991; Jonas et al., 2002; Meguro et al., 2007).  
The results discussed here do not imply that iron does not influence the 
development, behavior or progression of mammary gland carcinogenesis in the cat and in 
the dog. Actually, the fact that cats and dogs’ mammary epithelial cells accumulate much 
higher iron concentrations than in humans’ may also account for the high prevalence of 
cancer in those animals (Munson and Moresco, 2007), due to chronic cellular iron toxicity 
and oxidative stress (Nelson, 1992; Toyokuni, 1996; Eaton and Qian, 2002). In fact, 
estrogen and progesterone hormones are the single most important risk factor for the high 
incidence of mammary tumors in cats and dogs (Morrison, 1998; Baba and Câtoi, 2007). 
Previous studies have shown that estrogen metabolites in incubation with rat liver 
cytochrome P450 reductase and NADPH form superoxide radicals and reduce ferritin-
bound Fe3+ to Fe2+, potentially leading to the release of free, unbound iron (Wyllie and 
Liehr, 1997). This association between the redox cycling of catecholestrogen metabolites 
and the release of iron, through the generation of oxygen radicals (Liehr and Jones, 
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2001), has been proposed as a critical modulator of human breast cancer behavior and 
aggressiveness (Huang, 2008). It may also constitute an alternative explanation for the 
high hemosiderin accumulation in cats and dogs’ mammary gland epithelial cells.  
Our results are limited not only by the low number of cases, particularly of benign 
lesions in the cat mammary cohort, but ultimately by the fact that these were not 
representative of ‘normal’ mammary tissue, but of benign disease. One may argue that 
although histologically ‘normal’, benign alterations may already present several 
modifications that could mask real differences for the expression of cancer-intervenient 
proteins between samples. However, the electron microscopy studies were done in 
tissues from healthy animals, without any history of disease, and iron accumulation was 
clearly evident. Physiological differences in mammary iron uptake between species with 
high iron tissue levels, like the cat and the dog, and species with low iron levels, like the 
human species, should be clarified to verify if these animals are indeed suitable models of 
human breast cancer.  
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Supplementary Table 1. Immunoexpression of iron-related proteins in 
feline mammary gland tissue, per type of lesion. 
    
Hepcidin FPN1
2
 TFR1
3
 FT
4
 
(Mean ± SEM
1
) (Mean ± SEM) (Mean ± SEM) (Mean ± SEM) 
H
y
p
e
rp
la
s
ia
s
 
EC
5
 n= 5 n= 5 n= 5 n= 5 
  3.80 (± 0.92) 10 (± 0.00) 0.90 (± 0.68) 11.57 (± 0.67) 
Ly
6
 n= 3 n= 2 n= 5 n= 2 
  4.22 (± 2.12) 2.5 (± 0.50) 1.53 (0.76) 12.50 (± 0.00) 
M0
7
 n= 3 n= 2 n= 4 n= 4 
  10.33 (± 1.67) 4.50 (± 0.50) 8.75 (± 1.25) 14.38 (± 0.63) 
F
ib
ro
a
d
e
n
o
m
a
s
 
EC n= 3 n= 4 n= 4 n= 4 
  1.33 (± 0.33) 7.88 (± 2.02) 2.25 (± 0.75) 11.25 (± 1.61) 
Ly 
  
n=1  n= 1 
      0.00 12.5 
M0 
  
n=2  n= 4 
      5.50 (± 4.50) 15.00 (± 0.00) 
T
u
b
u
lo
p
a
p
p
ill
a
ry
 
C
a
rc
in
o
m
a
 
EC n= 31 n= 28 n= 31 n= 30 
  1.66 (± 0.38) 9.76 (± 0.69) 1.56 (± 0.33) 9.47 (± 0.52) 
Ly n= 16 n= 19 n= 26 n= 18 
  2.19 (± 0.79) 3.45 (± 0.52) 0.57 (± 0.27) 9.68 (± 0.91) 
M0 n= 16 n= 19 n= 24 n= 25 
  6.06 (± 0.80) 7.00 (± 0.73) 3.54 (± 0.74) 14.81 (± 0.13) 
S
o
lid
 C
a
rc
in
o
m
a
 EC n= 27 n= 23 n= 26 n= 26 
  2.03 (± 0.60) 9.78 (± 0.63) 1.21 (± 0.24) 8.77 (± 0.50) 
Ly n= 13 n= 14 n= 22 n= 16 
  2.88 (± 0.81) 3.07 (± 0.47) 1.32 (± 0.38) 7.79 (± 0.78) 
M0 n= 16 n= 16 n= 22 n= 23 
  7.69 (± 0.91) 7.93 (± 0.75) 3.00 (± 0.76) 15.00 (± 0.00) 
1
SEM, Standard Error of the Mean; 
2
FPN1, Ferroportin 1; 
3
TFR1, Transferrin Receptor 1; 
4
FT, 
Ferritin; 
5
EC, Epithelial Cells; 
6
Ly, Lymphocytes; 
7
M0, Macrophages 
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Supplementary Table 2 Immunoexpression of iron-related 
proteins in canine mammary gland tissue, per type of lesion. 
 
  
Hepcidin FPN1
2
 TFR1
3
 FT
4
 
(Mean ± SEM
1
) (Mean ± SEM) (Mean ± SEM) (Mean ± SEM) 
H
y
p
e
rp
la
s
ia
s
 
EC
5
 n= 6 n= 5 n= 4 n= 5 
  1.33 (± 0.85) 11.50 (± 2.21) 1.50 (± 0.50) 9.17 (± 1.44) 
Ly
6
 n= 2 n= 2 n= 4 n= 3 
  1.00 (± 0.00) 6.67 (± 4.26) 0.38 (± 0.24) 4.67 (± 1.67) 
M0
7
 n= 1 n= 2 n= 4 n= 4 
  8.00 9.00 (± 1.00) 6.75 (± 1.97) 13.75 (± 1.25) 
A
d
e
n
o
m
a
s
 
EC n= 11 n= 9 n= 11 n= 11 
  1.80 (± 0.30) 9.23 (± 0.96) 3.27 (± 0.95) 10.45 (± 0.82) 
Ly n= 4 n= 3 n= 7 n= 4 
  2.38 (± 0.63) 4.77 (± 1.32) 1.04 (± 0.30) 11.50 (± 2.18) 
M0 n= 6 n= 4 n= 11 n= 9 
  12.43 (± 0.95) 6.38 (± 1.52) 8.18 (± 0.76) 15.00 (± 0.00) 
B
e
n
ig
n
 M
M
T
 
EC n= 8 n= 7 n= 9 n= 9 
  1.81 (± 0.45) 10.12 (± 1.00) 3.00 (± 0.66) 10.00 (± 0.83) 
Ly n= 4 n= 2 n= 8 n= 3 
  1.00 (± 0.46) 7.00 (±  3.00) 0.67 (± 0.32) 8.67 (± 0.67) 
M0 n= 4 n= 3 n= 8 n= 9 
  12.38 (± 1.68) 11.68 (± 1.67) 7.13 (± 1.12) 15.00 (± 0.00) 
T
u
b
u
lo
p
a
p
p
ill
a
ry
 
C
a
rc
in
o
m
a
 
EC n= 12 n=11 n= 10 n= 10 
  0.88 (± 0.35) 11.29 (± 1.13) 2.75 (± 0.42) 9.92 (± 0.69) 
Ly n= 7 n= 7 n= 9 n= 6 
  2.36 (± 0.98) 4.41 (±  1.16) 1.17 (± 0.40) 8.00 (± 0.89) 
M0 n= 5 n= 8 n= 9 n= 8 
  6.80 (± 2.42) 6.88 (± 0.82) 7.78 (± 0.88) 15.00 (± 0.00) 
S
o
lid
 C
a
rc
in
o
m
a
 EC n= 11 n= 10 n= 11 n= 10 
  2.31 (± 0.63) 11.15 (± 0.85) 2.32 (± 0.60) 9.75 (± 0.58) 
Ly n= 5 n= 7 n= 9 n= 4 
  2.70 (± 0.98) 5.06 (± 1.71) 1.17 (± 0.40) 10.25 (± 1.65) 
M0 n= 4 n= 8 n= 7 n= 11 
  10.50 (± 1.94) 8.71 (± 0.84) 7.71 (± 0.87) 14.77 (± 0.22) 
C
o
m
p
le
x
 C
a
rc
in
o
m
a
 EC n= 12 n= 10 n= 11 n=12 
  1.17 (± 0.45) 9.33 (± 1.07) 2.15 (0.51) 10.56 (± 0.68) 
Ly n= 8 n= 7 n= 10 n= 8 
  3.35 (± 1.10) 4.94 (±  1.11) 1.12 (± 0.50) 9.39 (± 1.14) 
M0 n= 6 n= 8 n= 11 n= 12 
  9.67 (± 1.87) 7.69 (± 0.88) 8.41 (± 0.70) 15.00 (± 0.00) 
1
SEM, Standard Error of the Mean; 
2
FPN1, Ferroportin 1; 
3
TFR1, Transferrin 
Receptor 1; 
4
FT, Ferritin; 
5
EC, Epithelial Cells; 
6
Ly, Lymphocytes; 
7
M0, 
Macrophages 
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7.1. General Discussion 
 
Despite continuous development of novel diagnostic and technological tools for the 
management of breast cancer, many tumors still become chemo-resistant and progress to 
metastatic disease. This is when they become potentially fatal. Extensive data validates 
the fact that the accumulation of genetic and epigenetic mutations in breast epithelial cells 
is not enough to drive tumor progression, indicating a role for the host tissue 
microenvironment. The work presented throughout this thesis, by demonstrating that iron 
homeostasis deregulation is not restricted to breast cancer cells but also to stromal cells, 
adds new evidence to the hypothesized role of cells of the tissue microenvironment, such 
as lymphocytes and macrophages, as promoters of tumor progression through local 
regulation of iron homeostasis. 
Several pathways have been proposed for iron-related carcinogenesis, such as 
cellular damage by iron-induced oxidative stress [1, 2] and iron-promoted cell proliferation 
[3, 4]. In the last few decades, breast cancer has seen a prolific growth in the knowledge 
of its iron metabolism. From the primordial studies describing serum and breast tissue 
ferritin content and the association with breast cancer risk and recurrence [5, 6], to the 
more recent ones unveiling the role of the ferroportin-hepcidin axis [7, 8], we have come a 
long way in unraveling the mechanisms behind tumoral epithelial cell iron regulation 
derangement. Overall, breast cancer epithelial cells present an ‘iron-deficient’ phenotype 
with an increased expression of proteins associated with iron acquisition [9-11] and lower 
expression of proteins linked to iron export and storage [7, 8, 12, 13], as it happens with 
other types of tumors [14, 15]. Here we describe an alternative ‘iron-utilization’ phenotype 
for breast cancer cells with simultaneous increased expression of TFR1 and hepcidin, and 
decreased expression of FT, which is consistent with a proliferative status in which iron 
availability is crucial. A recent shift in breast cancer has been occurring by focusing on the 
role of stromal cells. Given the fact that genetic and epigenetic alterations known to 
regulate breast morphogenesis are the main initiators of breast carcinogenesis and since 
most breast ductal cells are weakly invasive, both in vitro and in vivo, it is very likely that 
stromal cells might be, in part, responsible for facilitating the progression from pre-
malignant lesions to invasive breast cancer [16, 17]. In this regard, the study of stromal 
inflammatory cells, as lymphocytes and macrophages, such important players in the 
regulation of systemic iron homeostasis, is lacking in the context of breast tumorigenesis 
[18]. Herein, we present, for the first time, a description of the iron-related phenotype of 
tumor-infiltrating lymphocytes and macrophages in breast carcinomas, and compare them 
with normal breast reduction tissue-resident counterparts. We demonstrated that, in 
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primary breast carcinomas, these cells present an ‘iron-donor’ phenotype as 
demonstrated by their higher expression of FPN1 and FT, while maintaining an activated 
profile seen by the increased expression of hepcidin and TFR1. These results are in 
concordance with the proposed idea that the surveillance role of the cells of the immune 
system against iron toxicity may favor tumor growth, either through supply of this critical 
element or by promoting angiogenesis [19, 20]. FPN1 was first discovered in 2000, by 
three independent groups [21-23], and shown soon after to be the receptor for hepcidin, 
and the only known iron exporter described to date [24, 25]. Since then, several groups 
have demonstrated that FPN1 may also be transcriptionally and postranscriptionally 
regulated by heme [26, 27], iron levels [26, 28-30], hypoxia [31-33] or even cytokines [34-
36]. Our results, in primary breast tumors and metastized lymph nodes show a 
concomitant overexpression of hepcidin, FPN1, TFR1 and FT in lymphocytes and 
macrophages. Although unexpected, the simultaneous overexpression of these proteins is 
plausible mainly in neoplastic context and in a tissue with higher iron levels than normal 
counterparts that might modulate the phenotype of immune system cells. In a neoplastic 
setting where angiogenesis is promoted to supply nutrients and oxygen essential to tumor 
growth and metastasis, red blood cell incoming might trigger or maintain these alterations 
[37]. In fact, heme may be the responsible driver of this FPN overexpression, 
independently of hepcidin levels, at least in macrophages [25, 26].  Heme is also a potent 
transcriptional activator of FTL and FTH genes. Additionally, the secretion of ferritin by 
macrophages and lymphocytes, previously demonstrated by others [38, 39], may engage 
in a feedback loop that further promotes angiogenesis. Coffman and coworkers have 
shown that ferritin blocks the antiangiogenic effects of the cleaved high molecular weight 
kininogen (HKa) in endothelial cells, namely induction of apoptosis, inhibition of migration 
and inhibition of tube formation. Furthermore, they also demonstrated that ferritin restored 
migration and survival of HKa-treated cells in vitro and preserved tumor-dependent vessel 
growth in the presence of HKa in vivo [40]. These evidences advocate another role for 
ferritin, besides an iron storage or mitogenic protein, as a regulator of tumor-associated 
angiogenesis. Phenotypic characterization of breast tissue macrophages revealed an 
increased expression of CD163, a high-affinity scavenge receptor for hemoglobin-
haptoglobin complexes [41], in carcinomas. The tumor-associated macrophages 
phenotype observed is consistent with the described for M2 macrophages by Recalcati et 
al. with an upregulation of FPN1 and resulting capacity to sustain malignant cell growth 
through iron release [20]. Although the phenotype is not fully recapitulated due to 
divergences in the expression of TFR1 and FT we cannot rule out the influence of tissue 
elements, as mentioned above, that are not reproducible in vitro. Regarding lymphocytes, 
although previous studies suggest a different ability to handle iron between CD4+ and 
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CD8+ T-lymphocytes [42, 43], we did not observe a particular lymphocyte profile 
associated with increased FPN1 and FT expression. 
Considering that lymphocytes and macrophages may constitute ‘iron-donor’ cells 
in charge of tissue ‘iron-nutrition’, we asked  if their ‘iron-profiles’ could also be deviated in 
case of metastasis. Overall, as for the primary tumor, we observed an increase in the 
expression of proteins related to iron export (FPN1 and FT) in lymphocyte/ macrophage 
areas of metastized lymph-nodes of patients with breast cancer, when compared with 
non-metastized ones. Lymph nodes are the most frequent sites for metastasis and there 
are probably several reasons for this, besides organ proximity, such as the lack of a 
basement membrane in lymphatic vessels and low pressure lymphatic fluid [44].  
However, it is probable that cell-cell communication and secretion of factors may to some 
extent mimic what happens in the primary tumor, at least to allow the settling of the first 
metastatic cell. It is long known that not only malignant cells are capable of changing their 
microenvironment, but also that an abnormal stroma is capable of enhancing the 
malignant potential of epithelial cells [45]. So, it is a question of whether the metastatic 
cells hijack the control of stromal cells’ iron metabolism in their favor by importing the iron 
released via-FPN1 or FT by them, or if a previously activated stroma (as seen in non-
metastized lymph from patients with metastized breast cancer, with higher FPN1 
expression than lymph nodes from patients with non-metastized breast cancer; 
unpublished results) may facilitate epithelial cell settling in a more favorable 
microenvironment [46, 47]. Therefore, the development of a pre-metastatic niche is, as a 
matter of fact, very similar to that of the primary tumor stroma, in which the progress of an 
inflammatory microenvironment co-evolves with the genetic and epigenetic changes in 
cancer cells [47, 48].  
The fact that we found FPN1 overexpression in lymphocytes and macrophages to 
be as high in benign lesions of the breast as in ductal carcinomas (unpublished 
observation) led us to think that this mechanism may constitute a common physiological 
nutrition task (as ‘iron-deliverers’, once FPN1 expression is also observed, to a minor 
extent in reduction mastectomy specimens) or rather a tissue alteration more primordial 
than would be initially thought. In fact, there are several similarities in stromal-breast 
epithelial relationships between mammary gland development and breast carcinogenesis 
[49, 50]. Changes in the breast microenvironment can happen earlier than in DCIS stages 
where proliferating breast epithelial cells can secrete chemokines which may lead to the 
accumulation of leukocytes, mesenchymal stem cells, endothelial cells and fibroblasts [17, 
51, 52]. This may often lead to inflammation and fibrosis (which are also involved in 
wound healing-response and exist in benign lesions before carcinoma) and induce even 
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more alterations in the breast microenvironment, ultimately driving breast tumorigenesis 
[53, 54].  In this sense, in precursor lesions, a more reactive stroma in which stromal 
inflammatory cells actively export more iron, can not only promote the proliferation 
(aberrant or not) of breast epithelial cells but also the development of alternative stromal-
cell alterations related to the deposition of iron in the tissue.  
The fact that precursor lesions already display iron-related alterations in the tumor 
microenvironment (either as a cause or consequence) is also patent in our second study 
of the association between CCL2 expression and the modulation of tissue iron levels in 
the breast. We demonstrate that epithelial and stromal inflammatory cells from non-
neoplastic breast tissue microenvironments, adjacent to carcinomas, already present iron 
accumulation, unlike breast aesthetic reduction specimens. Iron accumulation on stromal 
inflammatory cells, in turn, is associated with the expression of CCL2 in breast epithelial 
cells. CCL2 is a chemotactic cytokine with a role in breast cancer progression through an 
established positive feedback loop mechanism with macrophages that promotes 
angiogenesis, epithelial cell migration and metastasis [55-58]. CCL2 expression had been 
previously described to be influenced by cellular iron levels and modulated by HFE 
variants [59-63]. Recently, our group has demonstrated that CCL2 is an inhibitor of TFR1 
expression and that Ccl2-/- mice present elevated iron levels, splenic iron overload and 
mild iron accumulation in the liver, due to hepcidin-independent reduction of ferroportin 
levels [64] (unpublished results). Thus, epithelial cell secretion of CCL2, even in precursor 
lesions, may recruit leukocytes to the tissue milieu that can further support epithelial cell 
proliferation, either by recruiting more leukocytes, as reflected by the association between 
CCL2-positive macrophages and total macrophage infiltration, and/ or by iron delivery. 
Overall, these results add evidence to the proposed paracrine signaling interplay between 
epithelial cells and macrophages, where overexpression of CCL2 may be responsible for 
the attraction of iron-loaded leukocytes and consequent iron export to the tissue 
microenvironment. 
In addition, our results highlight another layer of iron-related regulation by backing 
up studies that suggest that HFE variants may modulate neoplastic cell behavior [65, 66]. 
Since HFE variants are highly prevalent, the possibility of understanding how they 
influence breast cancer progression, risk and treatment is of extreme importance. The 
hypothesis that HFE variants are associated with breast cancer aggressiveness lies on 
the observation that the lack of a functional HFE protein product increases iron absorption 
and favors tumor oxidative stress and genomic instability [67, 68]. In our study we provide 
a possible explanation for HFE variant regulation of breast cancer behavior by showing 
that p.C282Y heterozygous IDC patients present a significantly higher expression of 
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hepcidin in lymphocytes and macrophages than wild-type and H63D carrier patients and 
that p.C282Y/p.H63D compound heterozygotes also display a significantly higher 
expression of TFR1 in all the cell types analyzed, which may promote increased 
intracellular iron content. However, in our study no associations were found between HFE 
variants and clinicopathological markers of breast cancer progression and prognosis, 
therefore precluding any important role of HFE variants as biomarkers in breast cancer 
management. Nevertheless, despite much of the focus on HFE and cancer being linked to 
its regulation of iron homeostasis, a connection with the immune system cannot be 
disregarded. For instance, hereditary hemochromatosis patients present significantly 
lower lymphocyte counts [69] and disease severity is correlated with CD8 T-lymphocyte 
numbers [70, 71]. Furthermore, recent studies suggest that HFE acts as a negative 
regulator of CD8 T-lymphocyte activation [72] and influences CD8 T-cell differentiation 
and maturation [73]. On the other hand, activated T-lymphocytes are able to downregulate 
HFE expression in tumor cell lines, through production of TNF and IFN-γ [74]. In this 
sense, our results on the overexpression of hepcidin and TFR1 on lymphocytes and 
macrophages add relevant information for the view on how HFE may influence the cells of 
the immune system in a specific neoplastic context. 
Animals develop many diseases that also affect humans, including cancer. For this 
reason, animal models in which spontaneous malignant tumors arise constitute an 
important and valuable tool for cancer studies. In the end, the main objective is to 
understand key factors for the disease initiation and progression that may eventually help 
in the development of new therapies. Advantages for the use of cats and dogs in breast 
cancer studies over other animals include: (1) the fact that they are outbred animals, 
contrarily to some inbred mice and rats; (2) mammary gland tumors are spontaneous and 
not induced; (3) tumors are histologically similar and respond comparably to conventional 
therapies; (4) they share environmental factors with humans; (5) malignant tumors 
develop more rapidly due to their shorter life expectancy; (6) clinical trials produce more 
results due to a shorter life expectancy [75]. Furthermore, several underlying genetic and 
cytogenetic alterations were demonstrated to be common denominators between feline 
and canine mammary gland tumors and human breast cancer [76]. Nonetheless some 
doubts remain as to whether results obtained in pets’ mammary gland tumors are 
transferable to human breast cancer, due to differences such as the high proportion of 
feline mammary gland tumor’s hormone receptor negative when compared with its human 
breast counterparts [77, 78]. Regarding this, we dissected the iron-phenotype of breast 
epithelial cells, lymphocytes and macrophages from cats and dogs’ benign lesions and 
mammary gland tumors. Unexpectedly, we found no significant differences in the 
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expression of iron-related proteins between lesions, that could be explained by the 
accumulation of iron in normal mammary gland and benign lesions. Given this fact, our 
results add evidence to the fact that cats and dogs may not be good comparative 
oncology models for human breast cancer, at least regarding the deregulation of iron 
homeostasis. 
Overall, the results described in this thesis demonstrate that the deregulation of 
iron homeostasis in human breast cancer is a common denominator in several cell types, 
and that the expression of iron-related proteins in these cells is associated with 
clinicopathological markers of breast cancer behavior and progression. In this sense, it 
becomes increasingly critical to acknowledge the role of stromal cells in breast 
carcinogenesis and deepen the knowledge concerning the interactions with epithelial cells 
in order to clarify what these new prognostic markers indicate in biological context. 
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7.2. Conclusions and Future Perspectives 
 
In this thesis we report, for the first time, the expression of iron-related proteins in 
lymphocytes and macrophages from the breast tissue microenvironment. We demonstrate 
that breast ductal carcinoma infiltrating lymphocytes and macrophages present an ‘iron-
donor’ phenotype, as observed by its higher FPN1 and FT expression than in aesthetic 
reduction specimens. Strikingly, this phenotype is also observed in metastized lymph-
nodes. Additionally, markers of breast cancer behavior and prognosis were shown to be 
associated with the expression of iron-related proteins not only in epithelial cells but also 
in lymphocytes and macrophages. Once FPN1 expression in these stromal inflammatory 
cells is not associated with hepcidin expression nor iron accumulation, we hypothesized 
that CCL2, a chemokine previously shown to modulate iron regulation (and vice-versa), 
could be modulating tissue iron levels in the breast. In fact, an increase in the expression 
of CCL2 in epithelial cells was correlated with higher FPN1 expression in lymphocytes. 
Although we did not observe any modulation of CCL2 expression in epithelial cells or 
macrophages by HFE polymorphisms, as previously reported, we did recognize an 
increased expression of hepcidin and TFR1 (in all the cell types analyzed) in HFE 
p.C282Y/p.H63D compound heterozygous patients, which can provide a possible 
explanation for the previously reported findings of a more aggressive course of disease in 
p.C282Y carriers. Finally, we concluded that cats and dogs do not seem to be good 
animal models for the study of iron homeostasis in human breast cancer since they do not 
recapitulate the differences in the expression of iron-related proteins between 
normal/benign and carcinoma tissue. Nevertheless, this study gave us the opportunity to 
describe, for the first time, the remarkable iron accumulation in normal epithelial cells from 
cats and dogs’ mammary gland, unlike the normal human breast. 
We believe our results are of relevance, not only in terms of advancing knowledge 
about iron metabolism regulation in a particular tissue context, but also the 
acknowledgment of previously unforeseen roles of the tissue microenvironment 
inflammatory cells in the tumor context. In spite of the advances, several questions remain 
to be answered and points to be proven. 
It is of mounting importance to continue exploring the consequences of the cellular 
‘iron-donor’ phenotype, by performing functional essays in co-culture or three dimensional 
cell systems. Furthermore, extending our results by verifying the impact of CCL2 
neutralization on mammary gland iron levels and FPN1 expression in lymphocytes would 
add support to our view on the paracrine signaling interplay between malignant epithelial 
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cells and macrophages, where CCL2 overexpression is responsible for the recruitment of 
iron-loaded leukocytes that may increase tissue iron-loading through overexpression of 
FPN1.One must not forget, also, the pleiotropic roles of ferritin. The fact that ferritin 
expression is increased not only in carcinoma-infiltrating lymphocytes but also in 
metastized lymph-nodes, and is not associated with iron accumulation, suggests an 
alternative role for ferritin apart from its iron storage properties.  
The breast cancer patient cohort should be extended in order to validate the 
results observed in p.C282Y heterozygous breast cancer patients. Given that 
p.C282Y/p.H63D compound heterozygous patients present a higher expression of 
hepcidin and TFR1, and this phenotype is associated with a more aggressive disease 
behavior, it should be worthwhile analyzing if HFE variants have a real impact in breast 
cancer progression and prognosis in larger multicentric studies. 
Of particular interest is the fact that current cancer-related therapies include two, if 
not antagonizing, at least, competing views: (1) on one side iron-chelation is increasingly 
studied as a possible therapeutic alternative. In fact, given our results, iron chelation 
would be expected to impair malignant cell proliferation not only by direct limitation of iron 
bioavailability but also by blocking iron-delivery by cells of the tissue microenvironment; 
(2) on the other, iron replacement therapy is recommended in patients with cancer-related 
anemia. Thus, if circulating immune cells are capable of taking up iron and deposit it in 
other tissues, to what extent are we assisting the tumor, an entity capable of recruiting 
leukocytes in its own favor? In this sense, a deeper knowledge on the consequences of 
intravenous iron administration and how tissue microenvironment cells contribute to local 
iron regulation is of vital importance.  
Finally, the recognition that normal epithelial cells from cats and dogs’ mammary 
gland accumulate iron, unlike in the normal human breast, demands a deeper insight into 
the functional consequences and influences upon long time exposure. 
  
 
